



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07H 21/04, C12N 15/00, 15/63</b>		A1	(11) International Publication Number: <b>WO 96/40724</b> (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: <b>PCT/US96/10082</b> (22) International Filing Date: <b>7 June 1996 (07.06.96)</b> (30) Priority Data: <b>08/486,139</b> <b>7 June 1995 (07.06.95)</b> <b>US</b> (60) Parent Application or Grant (63) Related by Continuation <b>US</b> <b>08/486,139 (CIP)</b> <b>Filed on</b> <b>7 June 1995 (07.06.95)</b> (71) Applicant (for all designated States except US): <b>LIFE TECHNOLOGIES, INC. (US/US); 8717 Grovemont Circle, Gaithersburg, MD 20884-9980 (US).</b> (72) Inventors; and (73) Inventors/Applicants (for US only): <b>HARTLEY, James, L. (US/US); 7409 Hillside Drive, Frederick, MD 21702 (US). BRASCH, Michael, A. (US/US); 20931 Sunnycroft Road, Gaithersburg, MD 20882 (US).</b> (74) Agents: <b>ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein &amp; Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TO).</b>  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: <b>RECOMBINANTAL CLONING USING ENGINEERED RECOMBINATION SITES</b>			
(57) Abstract <p>Recombinational cloning is provided by the use of nucleic acids, vectors and methods, <i>in vitro</i> and <i>in vivo</i>, for moving or exchanging segments of DNA molecules using engineered recombination sites and recombination proteins to provide chimeric DNA molecules that have the desired characteristic(s) and/or DNA segment(s).</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## Recombinational Cloning Using Engineered Recombination Sites

5

### *Background of the Invention*

#### *Field of the Invention*

10           The present invention relates to recombinant DNA technology. DNA and  
vectors having engineered recombination sites are provided for use in a  
recombinational cloning method that enables efficient and specific recombination  
of DNA segments using recombination proteins. The DNAs, vectors and  
15           methods are useful for a variety of DNA exchanges, such as subcloning of DNA,  
*in vitro* or *in vivo*.

#### *Related Art*

20           *Site specific recombinases.* Site specific recombinases are enzymes that  
are present in some viruses and bacteria and have been characterized to have both  
endonuclease and ligase properties. These recombinases (along with associated  
proteins in some cases) recognize specific sequences of bases in DNA and  
exchange the DNA segments flanking those segments. The recombinases and  
associated proteins are collectively referred to as "recombination proteins" (*see*,  
*e.g.*, Landy, A., *Current Opinion in Biotechnology* 3:699-707 (1993)).

25           Numerous recombination systems from various organisms have been  
described. *See, e.g.*, Hoess *et al.*, *Nucleic Acids Research* 14(6):2287 (1986);  
Abremski *et al.*, *J. Biol. Chem.* 261(1):391 (1986); Campbell, J.

*Bacteriol.* 174(23):7495 (1992); Qian *et al.*, *J. Biol. Chem.* 267(11):7794 (1992); Araki *et al.*, *J. Mol. Biol.* 225(1):25 (1992); Maeser and Kahnmann (1991) *Mol. Gen. Genet.* 230:170-176).

Many of these belong to the integrase family of recombinases (Argos *et al.* *EMBO J.* 5:433-440 (1986)). Perhaps the best studied of these are the Integrase/*att* system from bacteriophage  $\lambda$  (Landy, A. *Current Opinions in Genetics and Devel.* 3:699-707 (1993)), the Cre/*loxP* system from bacteriophage P1 (Hoess and Abremski (1990) In *Nucleic Acids and Molecular Biology*, vol. 4. Eds.: Eckstein and Lilley, Berlin-Heidelberg: Springer-Verlag; pp. 90-109), and the FLP/FRT system from the *Saccharomyces cerevisiae* 2  $\mu$  circle plasmid (Broach *et al.* *Cell* 29:227-234 (1982)).

While these recombination systems have been characterized for particular organisms, the related art has only taught using recombinant DNA flanked by recombination sites, for *in vivo* recombination.

Backman (U.S. Patent No. 4,673,640) discloses the *in vivo* use of  $\lambda$  recombinase to recombine a protein producing DNA segment by enzymatic site-specific recombination using wild-type recombination sites *attB* and *attP*.

Hasan and Szybalski (*Gene* 56:145-151 (1987)) discloses the use of  $\lambda$  Int recombinase *in vivo* for intramolecular recombination between wild type *attP* and *attB* sites which flank a promoter. Because the orientations of these sites are inverted relative to each other, this causes an irreversible flipping of the promoter region relative to the gene of interest.

Palazzolo *et al.* *Gene* 88:25-36 (1990), discloses phage lambda vectors having bacteriophage  $\lambda$  arms that contain restriction sites positioned outside a cloned DNA sequence and between wild-type *loxP* sites. Infection of *E. coli* cells that express the Cre recombinase with these phage vectors results in recombination between the *loxP* sites and the *in vivo* excision of the plasmid replicon, including the cloned cDNA.

Pósfai *et al.* (*Nucl. Acids Res.* 22:2392-2398 (1994)) discloses a method for inserting into genomic DNA partial expression vectors having a selectable marker, flanked by two wild-type FRT recognition sequences. FLP site-specific recombinase as present in the cells is used to integrate the vectors into the

genome at predetermined sites. Under conditions where the replicon is functional, this cloned genomic DNA can be amplified.

Bebbee *et al.* (U.S. Patent No. 5,434,066) discloses the use of site-specific recombinases such as Cre for DNA containing two *loxP* sites is used for *in vivo* recombination between the sites.

Boyd (*Nucl. Acids Res.* 21:817-821 (1993)) discloses a method to facilitate the cloning of blunt-ended DNA using conditions that encourage intermolecular ligation to a dephosphorylated vector that contains a wild-type *loxP* site acted upon by a Cre site-specific recombinase present in *E. coli* host cells.

Waterhouse *et al.* (PCT No. 93/19172 and *Nucleic Acids Res.* 21 (9):2265 (1993)) disclose an *in vivo* method where light and heavy chains of a particular antibody were cloned in different phage vectors between *loxP* and *loxP 511* sites and used to transfect new *E. coli* cells. Cre, acting in the host cells on the two parental molecules (one plasmid, one phage), produced four products in equilibrium: two different cointegrates (produced by recombination at either *loxP* or *loxP 511* sites), and two daughter molecules, one of which was the desired product.

In contrast to the other related art, Schlake & Bode (*Biochemistry* 33:12746-12751 (1994)) discloses an *in vivo* method to exchange expression cassettes at defined chromosomal locations, each flanked by a wild type and a spacer-mutated FRT recombination site. A double-reciprocal crossover was mediated in cultured mammalian cells by using this FLP/FRT system for site-specific recombination.

**Transposases.** The family of enzymes, the transposases, has also been used to transfer genetic information between replicons. Transposons are structurally variable, being described as simple or compound, but typically encode the recombinase gene flanked by DNA sequences organized in inverted orientations. Integration of transposons can be random or highly specific. Representatives such as Tn7, which are highly site-specific, have been applied to the *in vivo* movement of DNA segments between replicons (Lucklow *et al.*, *J. Virol.* 67:4566-4579 (1993)).

Devine and Boeke *Nucl. Acids Res.* 22:3765-3772 (1994), discloses the construction of artificial transposons for the insertion of DNA segments, *in vitro*, into recipient DNA molecules. The system makes use of the integrase of yeast TY1 virus-like particles. The DNA segment of interest is cloned, using standard methods, between the ends of the transposon-like element TY1. In the presence of the TY1 integrase, the resulting element integrates randomly into a second target DNA molecule.

**DNA cloning.** The cloning of DNA segments currently occurs as a daily routine in many research labs and as a prerequisite step in many genetic analyses. The purpose of these clonings is various, however, two general purposes can be considered: (1) the initial cloning of DNA from large DNA or RNA segments (chromosomes, YACs, PCR fragments, mRNA, etc.), done in a relative handful of known vectors such as pUC, pGem, pBlueScript, and (2) the subcloning of these DNA segments into specialized vectors for functional analysis. A great deal of time and effort is expended both in the initial cloning of DNA segments and in the transfer of DNA segments from the initial cloning vectors to the more specialized vectors. This transfer is called subcloning.

The basic methods for cloning have been known for many years and have changed little during that time. A typical cloning protocol is as follows:

- (1) digest the DNA of interest with one or two restriction enzymes;
- (2) gel purify the DNA segment of interest when known;
- (3) prepare the vector by cutting with appropriate restriction enzymes, treating with alkaline phosphatase, gel purify etc., as appropriate;
- (4) ligate the DNA segment to vector, with appropriate controls to estimate background of uncut and self-ligated vector;
- (5) introduce the resulting vector into an *E. coli* host cell;
- (6) pick selected colonies and grow small cultures overnight;
- (7) make DNA minipreps; and
- (8) analyze the isolated plasmid on agarose gels (often after diagnostic restriction enzyme digestions) r by PCR.

The specialized vectors used for subcloning DNA segments are functionally diverse. These include but are not limited to: vectors for expressing genes in various organisms; for regulating gene expression; for providing tags to aid in protein purification or to allow tracking of proteins in cells; for modifying the cloned DNA segment (e.g., generating deletions); for the synthesis of probes (e.g., riboprobes); for the preparation of templates for DNA sequencing; for the identification of protein coding regions; for the fusion of various protein-coding regions; to provide large amounts of the DNA of interest, etc. It is common that a particular investigation will involve subcloning the DNA segment of interest into several different specialized vectors.

As known in the art, simple subclonings can be done in one day (e.g., the DNA segment is not large and the restriction sites are compatible with those of the subcloning vector). However, many other subclonings can take several weeks, especially those involving unknown sequences, long fragments, toxic genes, unsuitable placement of restriction sites, high backgrounds, impure enzymes, etc. Subcloning DNA fragments is thus often viewed as a chore to be done as few times as possible.

Several methods for facilitating the cloning of DNA segments have been described, e.g., as in the following references.

Ferguson, J., *et al. Gene* 16:191 (1981), discloses a family of vectors for subcloning fragments of yeast DNA. The vectors encode kanamycin resistance. Clones of longer yeast DNA segments can be partially digested and ligated into the subcloning vectors. If the original cloning vector conveys resistance to ampicillin, no purification is necessary prior to transformation, since the selection will be for kanamycin.

Hashimoto-Gotoh, T., *et al. Gene* 41:125 (1986), discloses a subcloning vector with unique cloning sites within a streptomycin sensitivity gene; in a streptomycin-resistant host, only plasmids with inserts or deletions in the dominant sensitivity gene will survive streptomycin selection.

Accordingly, traditional subcloning methods, using restriction enzymes and ligase, are time consuming and relatively unreliable. Considerable labor is expended, and if two or more days later the desired subclone can not be found

among the candidate plasmids, the entire process must then be repeated with alternative conditions attempted. Although site specific recombinases have been used to recombine DNA *in vivo*, the successful use of such enzymes *in vitro* was expected to suffer from several problems. For example, the site specificities and efficiencies were expected to differ *in vitro*; topologically-linked products were expected; and the topology of the DNA substrates and recombination proteins was expected to differ significantly *in vitro* (see, e.g., Adams *et al*, *J. Mol. Biol.* 226:661-73 (1992)). Reactions that could go on for many hours *in vivo* were expected to occur in significantly less time *in vitro* before the enzymes became inactive. Multiple DNA recombination products were expected in the biological host used, resulting in unsatisfactory reliability, specificity or efficiency of subcloning. *In vitro* recombination reactions were not expected to be sufficiently efficient to yield the desired levels of product.

Accordingly, there is a long felt need to provide an alternative subcloning system that provides advantages over the known use of restriction enzymes and ligases.

### *Summary of the Invention*

The present invention provides nucleic acid, vectors and methods for obtaining chimeric nucleic acid using recombination proteins and engineered recombination sites, *in vitro* or *in vivo*. These methods are highly specific, rapid, and less labor intensive than what is disclosed or suggested in the related background art. The improved specificity, speed and yields of the present invention facilitates DNA or RNA subcloning, regulation or exchange useful for any related purpose. Such purposes include *in vitro* recombination of DNA segments and *in vitro* or *in vivo* insertion or modification of transcribed, replicated, isolated or genomic DNA or RNA.

The present invention relates to nucleic acids, vectors and methods for moving or exchanging segments of DNA using at least one engineered recombination site and at least one recombination protein to provide chimeric DNA molecules which have the desired characteristic(s) and/or DNA segment(s).



Generally, one or more parent DNA molecules are recombined to give one or more daughter molecules, at least one of which is the desired Product DNA segment or vector. The invention thus relates to DNA, RNA, vectors and methods to effect the exchange and/or to select for one or more desired products.

5 One embodiment of the present invention relates to a method of making chimeric DNA, which comprises

(a) combining *in vitro* or *in vivo*

(i) an Insert Donor DNA molecule, comprising a desired DNA segment flanked by a first recombination site and a second recombination site, wherein the first and second recombination sites do not recombine with each other;

10 (ii) a Vector Donor DNA molecule containing a third recombination site and a fourth recombination site, wherein the third and fourth recombination sites do not recombine with each other; and

15 (iii) one or more site specific recombination proteins capable of recombining the first and third recombinational sites and/or the second and fourth recombinational sites;

thereby allowing recombination to occur, so as to produce at least one Cointegrate DNA molecule, at least one desired Product DNA molecule which comprises said desired DNA segment, and optionally a Byproduct DNA molecule; and then, optionally,

20 (b) selecting for the Product or Byproduct DNA molecule.

Another embodiment of the present invention relates to a kit comprising a carrier or receptacle being compartmentalized to receive and hold therein at least one container, wherein a first container contains a DNA molecule comprising a vector having at least two recombination sites flanking a cloning site or a Selectable marker, as described herein. The kit optionally further comprises:

25 (i) a second container containing a Vector Donor plasmid comprising a subcloning vector and/or a Selectable marker of which one or both are flanked by one or more engineered recombination sites; and/or

(ii) a third container containing at least one recombination protein which recognizes and is capable of recombining at least one of said recombination sites.

Other embodiments include DNA and vectors useful in the methods of the present invention. In particular, Vector Donor molecules are provided in one embodiment, wherein DNA segments within the Vector Donor are separated either by, (i) in a circular Vector Donor, at least two recombination sites, or (ii) in a linear Vector Donor, at least one recombination site, where the recombination sites are preferably engineered to enhance specificity or efficiency of recombination.

One Vector Donor embodiment comprises a first DNA segment and a second DNA segment, the first or second segment comprising a Selectable marker. A second Vector Donor embodiment comprises a first DNA segment and a second DNA segment, the first or second DNA segment comprising a toxic gene. A third Vector Donor embodiment comprises a first DNA segment and a second DNA segment, the first or second DNA segment comprising an inactive fragment of at least one Selectable marker, wherein the inactive fragment of the Selectable marker is capable of reconstituting a functional Selectable marker when recombined across the first or second recombination site with another inactive fragment of at least one Selectable marker.

The present recombinational cloning method possesses several advantages over previous *in vivo* methods. Since single molecules of recombination products can be introduced into a biological host, propagation of the desired Product DNA in the absence of other DNA molecules (*e.g.*, starting molecules, intermediates, and by-products) is more readily realized. Reaction conditions can be freely adjusted *in vitro* to optimize enzyme activities. DNA molecules can be incompatible with the desired biological host (*e.g.*, YACs, genomic DNA, etc.), can be used. Recombination proteins from diverse sources can be employed, together or sequentially.

Other embodiments will be evident to those of ordinary skill in the art from the teachings contained herein in combination with what is known to the art.

### Brief Description of the Figures

Figure 1 depicts one general method of the present invention, wherein the starting (parent) DNA molecules can be circular or linear. The goal is to exchange the new subcloning vector D for the original cloning vector B. It is desirable in one embodiment to select for AD and against all the other molecules, including the Cointegrate. The square and circle are sites of recombination: *e.g.*, *loxP* sites, *att* sites, *etc.* For example, segment D can contain expression signals, new drug markers, new origins of replication, or specialized functions for mapping or sequencing DNA.

Figure 2A depicts an *in vitro* method of recombining an Insert Donor plasmid (here, pEZC705) with a Vector Donor plasmid (here, pEZC726), and obtaining Product DNA and Byproduct daughter molecules. The two recombination sites are *attP* and *loxP* on the Vector Donor. On one segment defined by these sites is a kanamycin resistance gene whose promoter has been replaced by the *tetOP* operator/promoter from transposon *Tn10*: See Sizemore *et al.*, *Nucl. Acids Res.* 18(10):2875 (1990). In the absence of *tet* repressor protein, *E. coli* RNA polymerase transcribes the kanamycin resistance gene from the *tetOP*. If *tet* repressor is present, it binds to *tetOP* and blocks transcription of the kanamycin resistance gene. The other segment of pEZC726 has the *tet* repressor gene expressed by a constitutive promoter. Thus cells transformed by pEZC726 are resistant to chloramphenicol, because of the chloramphenicol acetyl transferase gene on the same segment as *tetR*, but are sensitive to kanamycin. The recombinase-mediated reactions result in separation of the *tetR* gene from the regulated kanamycin resistance gene. This separation results in kanamycin resistance in cells receiving only the desired recombination products. The first recombination reaction is driven by the addition of the recombinase called Integrase. The second recombination reaction is driven by adding the recombinase Cre to the Cointegrate (here, pEZC7 Cointegrate).

Figure 2B depicts a restriction map of pEZC705.

Figure 2C depicts a restriction map of pEZC726.

Figure 2D depicts a restriction map of pEZC7 Cointegrate.

Figure 2E depicts a restriction map of Intprod.

Figure 2F depicts a restriction map of Intbypro.

Figure 3A depicts an *in vitro* method of recombining an Insert Donor plasmid (here, pEZC602) with a Vector Donor plasmid (here, pEZC629), and obtaining Product (here, EZC6prod) and Byproduct (here, EZC6Bypr) daughter molecules. The two recombination sites are *loxP* and *loxP 511*. One segment of pEZC629 defined by these sites is a kanamycin resistance gene whose promoter has been replaced by the *tetOP* operator/promoter from transposon *Tn10*. In the absence of *tet* repressor protein, *E. coli* RNA polymerase transcribes the kanamycin resistance gene from the *tetOP*. If *tet* repressor is present, it binds to *tetOP* and blocks transcription of the kanamycin resistance gene. The other segment of pEZC629 has the *tet* repressor gene expressed by a constitutive promoter. Thus cells transformed by pEZC629 are resistant to chloramphenicol, because of the chloramphenicol acetyl transferase gene on the same segment as *tetR*, but are sensitive to kanamycin. The reactions result in separation of the *tetR* gene from the regulated kanamycin resistance gene. This separation results in kanamycin resistance in cells receiving the desired recombination product. The first and the second recombination events are driven by the addition of the same recombinase, Cre.

Figure 3B depicts a restriction map of EZC6Bypr.

Figure 3C depicts a restriction map of EZC6prod.

Figure 3D depicts a restriction map of pEZC602.

Figure 3E depicts a restriction map of pEZC629.

Figure 3F depicts a restriction map of EZC6oint.

Figure 4A depicts an application of the *in vitro* method of recombinational cloning to subclone the chloramphenicol acetyl transferase gene into a vector for expression in eukaryotic cells. The Insert Donor plasmid, pEZC843, is comprised of the chloramphenicol acetyl transferase gene of *E. coli*, cloned between *loxP* and *attB* sites such that the *loxP* site is positioned at the 5'-end of the gene. The Vector Donor plasmid, pEZC1003, contains the cytomegalovirus eukaryotic promoter apposed to a *loxP* site. The supercoiled plasmids were combined with lambda Integrase and Cre recombinase *in vitro*.

After incubation, competent *E. coli* cells were transformed with the recombinational reaction solution. Aliquots of transformations were spread on agar plates containing kanamycin to select for the Product molecule (here CMVProd).

- 5           Figure 4B depicts a restriction map of pEZC843.  
            Figure 4C depicts a restriction map of pEZC1003.  
            Figure 4D depicts a restriction map of CMVBypro.  
            Figure 4E depicts a restriction map of CMVProd.  
            Figure 4F depicts a restriction map of CMVcoint.  
10          Figure 5A depicts a vector diagram of pEZC1301.  
            Figure 5B depicts a vector diagram of pEZC1305.  
            Figure 5C depicts a vector diagram of pEZC1309.  
            Figure 5D depicts a vector diagram of pEZC1313.  
            Figure 5E depicts a vector diagram of pEZC1317.  
15          Figure 5F depicts a vector diagram of pEZC1321.  
            Figure 5G depicts a vector diagram of pEZC1405.  
            Figure 5H depicts a vector diagram of pEZC1502.  
            Figure 6A depicts a vector diagram of pEZC1603.  
            Figure 6B depicts a vector diagram of pEZC1706.  
20          Figure 7A depicts a vector diagram of pEZC2901.  
            Figure 7B depicts a vector diagram of pEZC2913.  
            Figure 7C depicts a vector diagram of pEZC3101.  
            Figure 7D depicts a vector diagram of pEZC1802.  
            Figure 8A depicts a vector diagram of pGEX-2TK.  
25          Figure 8B depicts a vector diagram of pEZC3501.  
            Figure 8C depicts a vector diagram of pEZC3601.  
            Figure 8D depicts a vector diagram of pEZC3609.  
            Figure 8E depicts a vector diagram of pEZC3617.  
            Figure 8F depicts a vector diagram of pEZC3606.  
30          Figure 8G depicts a vector diagram of pEZC3613.  
            Figure 8H depicts a vector diagram of pEZC3621.  
            Figure 8I depicts a vector diagram of GST-CAT.

Figure 8J depicts a vector diagram of GST-phoA.

Figure 8K depicts a vector diagram of pEZC3201.

### ***Detailed Description of the Preferred Embodiments***

5 It is unexpectedly discovered in the present invention that subcloning reactions can be provided using recombinational cloning. Recombination cloning according to the present invention uses DNAs, vectors and methods, *in vitro* and *in vivo*, for moving or exchanging segments of DNA molecules using engineered recombination sites and recombination proteins. These methods provide chimeric DNA molecules that have the desired characteristic(s) and/or DNA segment(s).

10 The present invention thus provides nucleic acid, vectors and methods for obtaining chimeric nucleic acid using recombination proteins and engineered recombination sites, *in vitro* or *in vivo*. These methods are highly specific, rapid, and less labor intensive than what is disclosed or suggested in the related background art. The improved specificity, speed and yields of the present  
15 invention facilitates DNA or RNA subcloning, regulation or exchange useful for any related purpose. Such purposes include *in vitro* recombination of DNA segments and *in vitro* or *in vivo* insertion or modification of transcribed, replicated, isolated or genomic DNA or RNA.

### ***Definitions***

20 In the description that follows, a number of terms used in recombinant DNA technology are utilized extensively. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

25 Byproduct: is a daughter molecule (a new clone produced after the second recombination event during the recombinational cloning process) lacking the DNA which is desired to be subcloned.

Cointegrate: is at least one recombination intermediate DNA molecule of the present invention that contains both parental (starting) DNA molecules. It will usually be circular. In some embodiments it can be linear.

Host: is any prokaryotic or eukaryotic organism that can be a recipient of the recombinational cloning Product. A "host," as the term is used herein, includes prokaryotic or eukaryotic organisms that can be genetically engineered. For examples of such hosts, see Maniatis *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982).

Insert: is the desired DNA segment (segment A of Figure 1) which one wishes to manipulate by the method of the present invention. The insert can have one or more genes.

Insert Donor: is one of the two parental DNA molecules of the present invention which carries the Insert. The Insert Donor DNA molecule comprises the Insert flanked on both sides with recombination signals. The Insert Donor can be linear or circular. In one embodiment of the invention, the Insert Donor is a circular DNA molecule and further comprises a cloning vector sequence outside of the recombination signals (see Figure 1).

Product: is one or both the desired daughter molecules comprising the A and D or B and C sequences which are produced after the second recombination event during the recombinational cloning process (see Figure 1). The Product contains the DNA which was to be cloned or subcloned.

Promoter: is a DNA sequence generally described as the 5'-region of a gene, located proximal to the start codon. The transcription of an adjacent DNA segment is initiated at the promoter region. A repressible promoter's rate of transcription decreases in response to a repressing agent. An inducible promoter's rate of transcription increases in response to an inducing agent. A constitutive promoter's rate of transcription is not specifically regulated, though it can vary under the influence of general metabolic conditions.

Recognition sequence: Recognition sequences are particular DNA sequences which a protein, DNA, or RNA molecule (e.g., restriction endonuclease, a modification methylase, or a recombinase) recognizes and binds. For example, the recognition sequence for Cre recombinase is *loxP* which is a 34 base pair sequence comprised of two 13 base pair inverted repeats (serving as the recombinase binding sites) flanking an 8 base pair core sequence. See Figure 1 of Sauer, B., *Current Opinion in Biotechnology* 5:521-527 (1994). Other examples of recognition sequences are the *attB*, *attP*, *attL*, and *attR* sequences which are recognized by the recombinase enzyme  $\lambda$  Integrase. *attB* is an approximately 25 base pair sequence containing two 9 base pair core-type Int binding sites and a 7 base pair overlap region. *attP* is an approximately 240 base pair sequence containing core-type Int binding sites and arm-type Int binding sites as well as sites for auxiliary proteins IHF, FIS, and Xis. See Landy, *Current Opinion in Biotechnology* 3:699-707 (1993). Such sites are also engineered according to the present invention to enhance methods and products.

Recombinase: is an enzyme which catalyzes the exchange of DNA segments at specific recombination sites.

Recombinational Cloning: is a method described herein, whereby segments of DNA molecules are exchanged, inserted, replaced, substituted or modified, *in vitro* or *in vivo*.

Recombination proteins: include excisive or integrative proteins, enzymes, co-factors or associated proteins that are involved in recombination reactions involving one or more recombination sites. See, Landy (1994), *infra*.

Repression cassette: is a DNA segment that contains a repressor of a Selectable marker present in the subcloning vector.

Selectable marker: is a DNA segment that allows one to select for or against a molecule or a cell that contains it, often under particular conditions. These markers can encode an activity, such as, but not limited to, production of RNA, peptide, or protein, or can provide a binding site for RNA, peptides, proteins, inorganic and organic compounds or compositions and the like. Examples of Selectable markers include but are not limited to: (1) DNA segments that encode products which provide resistance against otherwise toxic



compounds (e.g., antibiotics); (2) DNA segments that encode products which are otherwise lacking in the recipient cell (e.g., tRNA genes, auxotrophic markers); (3) DNA segments that encode products which suppress the activity of a gene product; (4) DNA segments that encode products which can be readily identified (e.g., phenotypic markers such as  $\beta$ -galactosidase, green fluorescent protein (GFP), and cell surface proteins); (5) DNA segments that bind products which are otherwise detrimental to cell survival and/or function; (6) DNA segments that otherwise inhibit the activity of any of the DNA segments described in Nos. 1-5 above (e.g., antisense oligonucleotides); (7) DNA segments that bind products that modify a substrate (e.g. restriction endonucleases); (8) DNA segments that can be used to isolate a desired molecule (e.g. specific protein binding sites); (9) DNA segments that encode a specific nucleotide sequence which can be otherwise non-functional (e.g., for PCR amplification of subpopulations of molecules); and/or (10) DNA segments, which when absent, directly or indirectly confer sensitivity to particular compounds.

Selection scheme: is any method which allows selection, enrichment, or identification of a desired Product or Product(s) from a mixture containing the Insert Donor, Vector Donor, and/or any intermediates, (e.g. a Cointegrate) Byproducts. The selection schemes of one preferred embodiment have at least two components that are either linked or unlinked during recombinational cloning. One component is a Selectable marker. The other component controls the expression *in vitro* or *in vivo* of the Selectable marker, or survival of the cell harboring the plasmid carrying the Selectable marker. Generally, this controlling element will be a repressor or inducer of the Selectable marker, but other means for controlling expression of the Selectable marker can be used. Whether a repressor or activator is used will depend on whether the marker is for a positive or negative selection, and the exact arrangement of the various DNA segments, as will be readily apparent to those skilled in the art. A preferred requirement is that the selection scheme results in selection of or enrichment for only one or more desired Products. As defined herein, to select for a DNA molecule includes (a) selecting or enriching for the presence of the desired DNA molecule, and (b)

selecting or enriching against the presence of DNA molecules that are not the desired DNA molecule.

In one embodiment, the selection schemes (which can be carried out reversed) will take one of three forms, which will be discussed in terms of Figure 1. The first, exemplified herein with a Selectable marker and a repressor therefor, selects for molecules having segment *D* and lacking segment *C*. The second selects against molecules having segment *C* and for molecules having segment *D*. Possible embodiments of the second form would have a DNA segment carrying a gene toxic to cells into which the *in vitro* reaction products are to be introduced. A toxic gene can be a DNA that is expressed as a toxic gene product (a toxic protein or RNA), or can be toxic in and of itself. (In the latter case, the toxic gene is understood to carry its classical definition of "heritable trait".)

Examples of such toxic gene products are well known in the art, and include, but are not limited to, restriction endonucleases (e.g., *DpnI*) and genes that kill hosts in the absence of a suppressing function, e.g., *kicB*. A toxic gene can alternatively be selectable *in vitro*, e.g., a restriction site.

In the second form, segment *D* carries a Selectable marker. The toxic gene would eliminate transformants harboring the Vector Donor, Cointegrate, and Byproduct molecules, while the Selectable marker can be used to select for cells containing the Product and against cells harboring only the Insert Donor.

The third form selects for cells that have both segments *A* and *D* in *cis* on the same molecule, but not for cells that have both segments in *trans* on different molecules. This could be embodied by a Selectable marker that is split into two inactive fragments, one each on segments *A* and *D*.

The fragments are so arranged relative to the recombination sites that when the segments are brought together by the recombination event, they reconstitute a functional Selectable marker. For example, the recombinational event can link a promoter with a structural gene, can link two fragments of a structural gene, or can link genes that encode a heterodimeric gene product needed for survival, or can link portions of a replicon.

Site-specific recombinase: is a type of recombinase which typically has at least the following four activities: (1) recognition of one or two specific DNA sequences; (2) cleavage of said DNA sequence or sequences; (3) DNA topoisomerase activity involved in strand exchange; and (4) DNA ligase activity to reseal the cleaved strands of DNA. See Sauer, B., *Current Opinions in Biotechnology* 5:521-527 (1994). Conservative site-specific recombination is distinguished from homologous recombination and transposition by a high degree of specificity for both partners. The strand exchange mechanism involves the cleavage and rejoining of specific DNA sequences in the absence of DNA synthesis (Landy, A. (1989) *Ann. Rev. Biochem.* 58:913-949).

Subcloning vector: is a cloning vector comprising a circular or linear DNA molecule which includes an appropriate replicon. In the present invention, the subcloning vector (segment *D* in Figure 1) can also contain functional and/or regulatory elements that are desired to be incorporated into the final product to act upon or with the cloned DNA Insert (segment *A* in Figure 1). The subcloning vector can also contain a Selectable marker (contained in segment *C* in Figure 1).

Vector: is a DNA that provides a useful biological or biochemical property to an Insert. Examples include plasmids, phages, and other DNA sequences which are able to replicate or be replicated *in vitro* or in a host cell, or to convey a desired DNA segment to a desired location within a host cell. A Vector can have one or more restriction endonuclease recognition sites at which the DNA sequences can be cut in a determinable fashion without loss of an essential biological function of the vector, and into which a DNA fragment can be spliced in order to bring about its replication and cloning. Vectors can further provide primer sites, e.g., for PCR, transcriptional and/or translational initiation and/or regulation sites, recombinational signals, replicons, Selectable markers, etc. Clearly, methods of inserting a desired DNA fragment which do not require the use of homologous recombination or restriction enzymes (such as, but not limited to, UDG cloning of PCR fragments (U.S. Patent No. 5,334,575, entirely incorporated herein by reference), T:A cloning, and the like) can also be applied to clone a fragment of DNA into a cloning vector to be used according to the

present invention. The cloning vector can further contain a Selectable marker suitable for use in the identification of cells transformed with the cloning vector.

Vector Donor: is one of the two parental DNA molecules of the present invention which carries the DNA segments encoding the DNA vector which is to become part of the desired Product. The Vector Donor comprises a subcloning vector *D* (or it can be called the cloning vector if the Insert Donor does not already contain a cloning vector) and a segment *C* flanked by recombination sites (see Figure 1). Segments *C* and/or *D* can contain elements that contribute to selection for the desired Product daughter molecule, as described above for selection schemes. The recombination signals can be the same or different, and can be acted upon by the same or different recombinases. In addition, the Vector Donor can be linear or circular.

### *Description*

One general scheme for an *in vitro* or *in vivo* method of the invention is shown in Figure 1, where the Insert Donor and the Vector Donor can be either circular or linear DNA, but is shown as circular. Vector *D* is exchanged for the original cloning vector *A*. It is desirable to select for the daughter vector containing elements *A* and *D* and against other molecules, including one or more Cointegrate(s). The square and circle are different sets of recombination sites (e.g., *lox* sites or *att* sites). Segment *A* or *D* can contain at least one Selection Marker, expression signals, origins of replication, or specialized functions for detecting, selecting, expressing, mapping or sequencing DNA, where *D* is used in this example.

Examples of desired DNA segments that can be part of Element *A* or *D* include, but are not limited to, PCR products, large DNA segments, genomic clones or fragments, cDNA clones, functional elements, etc., and genes or partial genes, which encode useful nucleic acids or proteins. Moreover, the recombinational cloning of the present invention can be used to make *ex vivo* and *in vivo* gene transfer vehicles for protein expression and/or gene therapy.

In Figure 1, the scheme provides the desired Product as containing vectors *D* and *A*, as follows. The Insert Donor (containing *A* and *B*) is first recombined at the square recombination sites by recombination proteins, with the Vector Donor (containing *C* and *D*), to form a Co-integrate having each of A-D-C-B. Next, recombination occurs at the circle recombination sites to form Product DNA (*A* and *D*) and Byproduct DNA (*C* and *B*). However, if desired, two or more different Co-integrates can be formed to generate two or more Products.

In one embodiment of the present *in vitro* or *in vivo* recombinational cloning method, a method for selecting at least one desired Product DNA is provided. This can be understood by consideration of the map of plasmid pEZC726 depicted in Figure 2. The two exemplary recombination sites are *attP* and *loxP*. On one segment defined by these sites is a kanamycin resistance gene whose promoter has been replaced by the *tetOP* operator/promoter from transposon *Tn10*. In the absence of *tet* repressor protein, *E. coli* RNA polymerase transcribes the kanamycin resistance gene from the *tetOP*. If *tet* repressor is present, it binds to *tetOP* and blocks transcription of the kanamycin resistance gene. The other segment of pEZC726 has the *tet* repressor gene expressed by a constitutive promoter. Thus cells transformed by pEZC726 are resistant to chloramphenicol, because of the chloramphenicol acetyl transferase gene on the same segment as *tetR*, but are sensitive to kanamycin. The recombination reactions result in separation of the *tetR* gene from the regulated kanamycin resistance gene. This separation results in kanamycin resistance in cells receiving the desired recombination Product.

Two different sets of plasmids were constructed to demonstrate the *in vitro* method. One set, for use with Cre recombinase only (cloning vector 602 and subcloning vector 629 (Figure 3)) contained *loxP* and *loxP* 511 sites. A second set, for use with Cre and integrase (cloning vector 705 and subcloning vector 726 (Figure 2)) contained *loxP* and *att* sites. The efficiency of production of the desired daughter plasmid was about 60 fold higher using both enzymes than using Cre alone. Nineteen of twenty four colonies from the Cre-only

reaction contained the desired product, while thirty eight of thirty eight colonies from the integrase plus Cre reaction contained the desired product plasmid.

*Other Selection Schemes* A variety of selection schemes can be used that are known in the art as they can suit a particular purpose for which the recombinational cloning is carried out. Depending upon individual preferences and needs, a number of different types of selection schemes can be used in the recombinational cloning method of the present invention. The skilled artisan can take advantage of the availability of the many DNA segments or methods for making them and the different methods of selection that are routinely used in the art. Such DNA segments include but are not limited to those which encodes an activity such as, but not limited to, production of RNA, peptide, or protein, or providing a binding site for such RNA, peptide, or protein. Examples of DNA molecules used in devising a selection scheme are given above, under the definition of "selection scheme"

Additional examples include but are not limited to:

- (i) Generation of new primer sites for PCR (*e.g.*, juxtaposition of two DNA sequences that were not previously juxtaposed);
- (ii) Inclusion of a DNA sequence acted upon by a restriction endonuclease or other DNA modifying enzyme, chemical, ribozyme, etc.;
- (iii) Inclusion of a DNA sequence recognized by a DNA binding protein, RNA, DNA, chemical, etc.) (*e.g.*, for use as an affinity tag for selecting for or excluding from a population) (Davis, *Nucl. Acids Res.* 24:702-706 (1996); *J. Virol.* 69: 8027-8034 (1995));
- (iv) *In vitro* selection of RNA ligands for the ribosomal L22 protein associated with Epstein-Barr virus-expressed RNA by using randomized and cDNA-derived RNA libraries;
- (vi) The positioning of functional elements whose activity requires a specific orientation or juxtaposition (*e.g.*, (a) a recombination site which reacts poorly in trans, but when placed in cis, in the presence of the appropriate proteins, results in recombination that destroys certain populations of molecules; (*e.g.*, reconstitution of

a promoter sequence that allows *in vitro* RNA synthesis). The RNA can be used directly, or can be reverse transcribed to obtain the desired DNA construct;

- (vii) Selection of the desired product by size (*e.g.*, fractionation) or other physical property of the molecule(s); and
- (viii) Inclusion of a DNA sequence required for a specific modification (*e.g.*, methylation) that allows its identification.

After formation of the Product and Byproduct in the method of the present invention, the selection step can be carried out either *in vitro* or *in vivo* depending upon the particular selection scheme which has been optionally devised in the particular recombinational cloning procedure.

For example, an *in vitro* method of selection can be devised for the Insert Donor and Vector Donor DNA molecules. Such scheme can involve engineering a rare restriction site in the starting circular vectors in such a way that after the recombination events the rare cutting sites end up in the Byproduct. Hence, when the restriction enzyme which binds and cuts at the rare restriction site is added to the reaction mixture *in vitro*, all of the DNA molecules carrying the rare cutting site, *i.e.*, the starting DNA molecules, the Cointegrate, and the Byproduct, will be cut and rendered nonreplicable in the intended host cell. For example, cutting sites in segments *B* and *C* (see Figure 1) can be used to select against all molecules except the Product. Alternatively, only a cutting site in *C* is needed if one is able to select for segment *D*, *e.g.*, by a drug resistance gene not found on *B*.

Similarly, an *in vitro* selection method can be devised when dealing with linear DNA molecules. DNA sequences complementary to a PCR primer sequence can be so engineered that they are transferred, through the recombinational cloning method, only to the Product molecule. After the reactions are completed, the appropriate primers are added to the reaction solution and the sample is subjected to PCR. Hence, all or part of the Product molecule is amplified.

Other *in vivo* selection schemes can be used with a variety of *E. coli* cell lines. One is to put a repressor gene on one segment of the subcloning plasmid, and a drug marker controlled by that repressor on the other segment of the same

plasmid. Another is to put a killer gene on segment C of the subcloning plasmid (Figure 1). Of course a way must exist for growing such a plasmid, i.e., there must exist circumstances under which the killer gene will not kill. There are a number of these genes known which require particular strains of *E. coli*. One such scheme is to use the restriction enzyme *DpnI*, which will not cleave unless its recognition sequence GATC is methylated. Many popular common *E. coli* strains methylate GATC sequences, but there are mutants in which cloned *DpnI* can be expressed without harm.

Of course analogous selection schemes can be devised for other host organisms. For example, the *tet* repressor/operator of *Tn10* has been adapted to control gene expression in eukaryotes (Gossen, M., and Bujard, H., *Proc. Natl. Acad. Sci. USA* 89:5547-5551 (1992)). Thus the same control of drug resistance by the *tet* repressor exemplified herein can be applied to select for Product in eukaryotic cells.

### Recombination Proteins

In the present invention, the exchange of DNA segments is achieved by the use of recombination proteins, including recombinases and associated co-factors and proteins. Various recombination proteins are described in the art. Examples of such recombinases include:

**Cre:** A protein from bacteriophage P1 (Abremski and Hoess, *J. Biol. Chem.* 259(3):1509-1514 (1984)) catalyzes the exchange (i.e., causes recombination) between 34 bp DNA sequences called *loxP* (locus of crossover) sites (See Hoess *et al.*, *Nucl. Acids Res.* 14(5):2287 (1986)). Cre is available commercially (Novagen, Catalog No. 69247-1). Recombination mediated by Cre is freely reversible. From thermodynamic considerations it is not surprising that Cre-mediated integration (recombination between two molecules to form one molecule) is much less efficient than Cre-mediated excision (recombination between two *loxP* sites in the same molecule to form two daughter molecules). Cre works in simple buffers with either magnesium or spermidine as a cofactor, as is well known in the art. The DNA substrates can be either linear or



supercoiled. A number of mutant *loxP* sites have been described (Hoess *et al.*, *supra*). One of these, *loxP 511*, recombines with another *loxP 511* site, but will not recombine with a *loxP* site.

**Integrase:** A protein from bacteriophage lambda that mediates the integration of the lambda genome into the *E. coli* chromosome. The bacteriophage  $\lambda$  Int recombinational proteins promote irreversible recombination between its substrate *att* sites as part of the formation or induction of a lysogenic state. Reversibility of the recombination reactions results from two independent pathways for integrative and excisive recombination. Each pathway uses a unique, but overlapping, set of the 15 protein binding sites that comprise *att* site DNAs. Cooperative and competitive interactions involving four proteins (Int, Xis, IHF and FIS) determine the direction of recombination.

Integrative recombination involves the Int and IHF proteins and sites *attP* (240 bp) and *attB* (25 bp). Recombination results in the formation of two new sites: *attL* and *attR*. Excisive recombination requires Int, IHF, and Xis, and sites *attL* and *attR* to generate *attP* and *attB*. Under certain conditions, FIS stimulates excisive recombination. In addition to these normal reactions, it should be appreciated that *attP* and *attB*, when placed on the same molecule, can promote excisive recombination to generate two excision products, one with *attL* and one with *attR*. Similarly, intermolecular recombination between molecules containing *attL* and *attR*, in the presence of Int, IHF and Xis, can result in integrative recombination and the generation *attP* and *attB*. Hence, by flanking DNA segments with appropriate combinations of engineered *att* sites, in the presence of the appropriate recombination proteins, one can direct excisive or integrative recombination, as reverse reactions of each other.

Each of the *att* sites contains a 15 bp core sequence; individual sequence elements of functional significance lie within, outside, and across the boundaries of this common core (Landy, A., *Ann. Rev. Biochem.* 58:913 (1989)). Efficient recombination between the various *att* sites requires that the sequence of the central common region be identical between the recombining partners, however, the exact sequence is now found to be modifiable. Consequently, derivatives f

the *att* site with changes within the core are now discovered to recombine as least as efficiently as the native core sequences.

Integrase acts to recombine the *attP* site on bacteriophage lambda (about 240 bp) with the *attB* site on the *E. coli* genome (about 25 bp) (Weisberg, R.A. and Landy, A. in *Lambda II*, p. 211 (1983), Cold Spring Harbor Laboratory)), to produce the integrated lambda genome flanked by *attL* (about 100 bp) and *attR* (about 160 bp) sites. In the absence of Xis (see below), this reaction is essentially irreversible. The integration reaction mediated by integrase and IHF works *in vitro*, with simple buffer containing spermidine. Integrase can be obtained as described by Nash, H.A., *Methods of Enzymology* 100:210-216 (1983). IHF can be obtained as described by Filutowicz, M., *et al.*, *Gene* 147:149-150 (1994).

In the presence of the  $\lambda$  protein Xis (excise) integrase catalyzes the reaction of *attR* and *attL* to form *attP* and *attB*, i.e., it promotes the reverse of the reaction described above. This reaction can also be applied in the present invention.

**Other Recombination Systems.** Numerous recombination systems from various organisms can also be used, based on the teaching and guidance provided herein. See, e.g., Hoess *et al.*, *Nucleic Acids Research* 14(6):2287 (1986); Abremski *et al.*, *J. Biol. Chem.* 261(1):391 (1986); Campbell, *J. Bacteriol.* 174(23):7495 (1992); Qian *et al.*, *J. Biol. Chem.* 267(11):7794 (1992); Araki *et al.*, *J. Mol. Biol.* 225(1):25 (1992)). Many of these belong to the integrase family of recombinases (Argos *et al.* *EMBO J.* 5:433-440 (1986)). Perhaps the best studied of these are the Integrase/*att* system from bacteriophage  $\lambda$  (Landy, A. (1993) *Current Opinions in Genetics and Devel.* 3:699-707), the *Cre/loxP* system from bacteriophage P1 (Hoess and Abremski (1990) In *Nucleic Acids and Molecular Biology*, vol. 4. Eds.: Eckstein and Lilley, Berlin-Heidelberg: Springer-Verlag; pp. 90-109), and the FLP/FRT system from the *Saccharomyces cerevisiae* 2  $\mu$  circle plasmid (Broach *et al.* *Cell* 29:227-234 (1982)).

Members of a second family of site-specific recombinases, the resolvase family (e.g.,  $\gamma\delta$ , Tn3 resolvase, Hin, Gin, and Cin) are also known. Members of this highly related family of recombinases are typically constrained to intramolecular reactions (e.g., inversions and excisions) and can require host-

encoded factors. Mutants have been isolated that relieve some of the requirements for host factors (Maeser and Kahnmann (1991) *Mol. Gen. Genet.* 230:170-176), as well as some of the constraints of intramolecular recombination.

Other site-specific recombinases similar to  $\lambda$  Int and similar to P1 Cre can be substituted for Int and Cre. Such recombinases are known. In many cases the purification of such other recombinases has been described in the art. In cases when they are not known, cell extracts can be used or the enzymes can be partially purified using procedures described for Cre and Int.

While Cre and Int are described in detail for reasons of example, many related recombinase systems exist and their application to the described invention is also provided according to the present invention. The integrase family of site-specific recombinases can be used to provide alternative recombination proteins and recombination sites for the present invention, as site-specific recombination proteins encoded by bacteriophage lambda, phi 80, P22, P2, 186, P4 and P1. This group of proteins exhibits an unexpectedly large diversity of sequences. Despite this diversity, all of the recombinases can be aligned in their C-terminal halves.

A 40-residue region near the C terminus is particularly well conserved in all the proteins and is homologous to a region near the C terminus of the yeast 2 mu plasmid F1p protein. Three positions are perfectly conserved within this family: histidine, arginine and tyrosine are found at respective alignment positions 396, 399 and 433 within the well-conserved C-terminal region. These residues contribute to the active site of this family of recombinases, and suggest that tyrosine-433 forms a transient covalent linkage to DNA during strand cleavage and rejoining. See, e.g., Argos, P. et al., *EMBO J.* 5:433-40 (1986).

Alternatively, IS231 and other *Bacillus thuringiensis* transposable elements could be used as recombination proteins and recombination sites. *Bacillus thuringiensis* is an entomopathogenic bacterium whose toxicity is due to the presence in the sporangia of delta-endotoxin crystals active against agricultural pests and vectors of human and animal diseases. Most of the genes coding for these toxin proteins are plasmid-borne and are generally structurally associated with insertion sequences (IS231, IS232, IS240, ISBT1 and ISBT2) and transposons (Tn4430 and Tn5401). Several of these mobile elements have been

shown to be active and participate in the crystal gene mobility, thereby contributing to the variation of bacterial toxicity.

Structural analysis of the iso-IS231 elements indicates that they are related to IS1151 from *Clostridium perfringens* and distantly related to IS4 and IS186 from *Escherichia coli*. Like the other IS4 family members, they contain a conserved transposase-integrase motif found in other IS families and retroviruses.

Moreover, functional data gathered from IS231A in *Escherichia coli* indicate a non-replicative mode of transposition, with a preference for specific targets. Similar results were also obtained in *Bacillus subtilis* and *B. thuringiensis*. See, e.g., Mahillon, J. et al., *Genetica* 93:13-26 (1994); Campbell, J. *Bacteriol.* 7495-7499 (1992).

The amount of recombinase which is added to drive the recombination reaction can be determined by using known assays. Specifically, titration assay is used to determine the appropriate amount of a purified recombinase enzyme, or the appropriate amount of an extract.

**Engineered Recombination Sites.** The above recombinases and corresponding recombinase sites are suitable for use in recombination cloning according to the present invention. However, wild-type recombination sites contain sequences that reduce the efficiency or specificity of recombination reactions as applied in methods of the present invention. For example, multiple stop codons in attB, attR, attP, attL and loxP recombination sites occur in multiple reading frames on both strands, so recombination efficiencies are reduced, e.g., where the coding sequence must cross the recombination sites, (only one reading frame is available on each strand of loxP and attB sites) or impossible (in attP, attR or attL).

Accordingly, the present invention also provides engineered recombination sites that overcome these problems. For example, att sites can be engineered to have one or multiple mutations to enhance specificity or efficiency of the recombination reaction and the properties of Product DNAs (e.g., att1, att2, and att3 sites); to decrease reverse reaction (e.g., removing P1 and H1 from attB). The testing of these mutants determines which mutants yield sufficient

recombinational activity to be suitable for recombination subcloning according to the present invention.

5 Mutations can therefore be introduced into recombination sites for enhancing site specific recombination. Such mutations include, but are not limited to: recombination sites without translation stop codons that allow fusion proteins to be encoded; recombination sites recognized by the same proteins but differing in base sequence such that they react largely or exclusively with their homologous partners allow multiple reactions to be contemplated. Which particular reactions take place can be specified by which particular partners are present in the reaction mixture. For example, a tripartite protein fusion could be accomplished with parental plasmids containing recombination sites attR1 and attR2; attL1 and attL3; and/or attR3 and attL2.

10 There are well known procedures for introducing specific mutations into nucleic acid sequences. A number of these are described in Ausubel, F.M. *et al.*, *Current Protocols in Molecular Biology*, Wiley Interscience, New York (1989-1996). Mutations can be designed into oligonucleotides, which can be used to modify existing cloned sequences, or in amplification reactions. Random mutagenesis can also be employed if appropriate selection methods are available to isolate the desired mutant DNA or RNA. The presence of the desired mutations can be confirmed by sequencing the nucleic acid by well known methods.

20 The following non-limiting methods can be used to engineer a core region of a given recombination site to provide mutated sites suitable for use in the present invention:

- 25 1. By recombination of two parental DNA sequences by site-specific (e.g. attL and attR to give attB) or other (e.g. homologous) recombination mechanisms. The DNA parental DNA segments containing one or more base alterations resulting in the final core sequence;
- 30 2. By mutation or mutagenesis (site-specific, PCR, random, spontaneous, etc) directly of the desired core sequence;

3. By mutagenesis (site-specific, PCR, random, spontaneous, etc) of parental DNA sequences, which are recombined to generate a desired core sequence; and
4. By reverse transcription of an RNA encoding the desired core sequence.

The functionality of the mutant recombination sites can be demonstrated in ways that depend on the particular characteristic that is desired. For example, the lack of translation stop codons in a recombination site can be demonstrated by expressing the appropriate fusion proteins. Specificity of recombination between homologous partners can be demonstrated by introducing the appropriate molecules into *in vitro* reactions, and assaying for recombination products as described herein or known in the art. Other desired mutations in recombination sites might include the presence or absence of restriction sites, translation or transcription start signals, protein binding sites, and other known functionalities of nucleic acid base sequences. Genetic selection schemes for particular functional attributes in the recombination sites can be used according to known method steps. For example, the modification of sites to provide (from a pair of sites that do not interact) partners that do interact could be achieved by requiring deletion, via recombination between the sites, of a DNA sequence encoding a toxic substance. Similarly, selection for sites that remove translation stop sequences, the presence or absence of protein binding sites, etc., can be easily devised by those skilled in the art.

Accordingly, the present invention provides a nucleic acid molecule, comprising at least one DNA segment having at least two engineered recombination sites flanking a Selectable marker and/or a desired DNA segment, wherein at least one of said recombination sites comprises a core region having at least one engineered mutation that enhances recombination *in vitro* in the formation of a Cointegrate DNA or a Product DNA.

The nucleic acid molecule can have at least one mutation that confers at least one enhancement of said recombination, said enhancement selected from the group consisting of substantially (i) favoring excisive integration; (ii) favoring excisive recombination; (iii) relieving the requirement for host factors; (iii)

increasing the efficiency of said Cointegrate DNA or Product DNA formation; and (iv) increasing the specificity of said Cointegrate DNA or Product DNA formation.

The nucleic acid molecule preferably comprises at least one recombination site derived from attB, attP, attL or attR. More preferably the att site is selected from att1, att2, or att3, as described herein.

In a preferred embodiment, the core region comprises a DNA sequence selected from the group consisting of:

- (a) RKYCWGCTTTYKTRTACNAASTSGB (m-att) (SEQ ID NO:1);
- (b) AGCCWGCTTTYKTRTACNAACTSGB (m-attB) (SEQ ID NO:2);
- (c) GTTCAGCTTTCKTRTACNAACTSGB (m-attR) (SEQ ID NO:3);
- (d) AGCCWGCTTTCKTRTACNAAGTSGB (m-attL) (SEQ ID NO:4);
- (e) GTTCAGCTTTYKTRTACNAAGTSGB(m-attP1) (SEQ ID NO:5);

or a corresponding or complementary DNA or RNA sequence, wherein R=A or G; K=G or T/U; Y=C or T/U; W=A or T/U; N=A or C or G or T/U; S=C or G; and B=C or G or T/U, as presented in 37 C.F.R. §1.822, which is entirely incorporated herein by reference, wherein the core region does not contain a stop codon in one or more reading frames.

The core region also preferably comprises a DNA sequence selected from the group consisting of:

- (a) AGCCTGCTTTTTGTACAAACTTGT (attB1) (SEQ ID NO:6);
- (b) AGCCTGCTTCTTGACAAACTTGT (attB2) (SEQ ID NO:7);
- (c) ACCCAGCTTCTTGACAAACTTGT (attB3) (SEQ ID NO:8);
- (d) GTTCAGCTTTTTGTACAAACTTGT (attR1) (SEQ ID NO:9);
- (e) GTTCAGCTTCTTGACAAACTTGT (attR2) (SEQ ID NO:10);
- (f) GTTCAGCTTCTTGTACAAAGTTGG (attR3) (SEQ ID NO:11);

(g) AGCCTGCTTTTTGTACAAAGTTGG (attL1) (SEQ ID NO:12);

(h) AGCCTGCTTCTTGTACAAAGTTGG (attL2) (SEQ ID NO:13);

5 (i) ACCCAGCTTCTTGTACAAAGTTGG (attL3) (SEQ ID NO:14);

(j) GTTCAGCTTTTTGTACAAAGTTGG(attP1)(SEQ ID NO:15);

(k) GTTCAGCTTCTTGTACAAAGTTGG (attP2,P3) (SEQ ID NO:16); or a corresponding or complementary DNA or RNA sequence.

10 The present invention thus also provides a method for making a nucleic acid molecule, comprising providing a nucleic acid molecule having at least one engineered recombination site comprising at least one DNA sequence having at least 80-99% homology (or any range or value therein) to at least one of SEQ ID NOS:1-16, or any suitable recombination site, or which hybridizes under  
15 stringent conditions thereto, as known in the art.

Clearly, there are various types and permutations of such well-known *in vitro* and *in vivo* selection methods, each of which are not described herein for the sake of brevity. However, such variations and permutations are contemplated and considered to be the different embodiments of the present invention.

20 It is important to note that as a result of the preferred embodiment being *in vitro* recombination reactions, non-biological molecules such as PCR products can be manipulated via the present recombinational cloning method. In one example, it is possible to clone linear molecules into circular vectors.

25 There are a number of applications for the present invention. These uses include, but are not limited to, changing vectors, apposing promoters with genes, constructing genes for fusion proteins, changing copy number, changing replicons, cloning into phages, and cloning, *e.g.*, PCR products (with an *attB* site at one end and a *loxP* site at the other end), genomic DNAs, and cDNAs.



The following examples are intended to further illustrate certain preferred embodiments of the invention and are not intended to be limiting in nature.

### *Examples*

The present recombinational cloning method accomplishes the exchange of nucleic acid segments to render something useful to the user, such as a change of cloning vectors. These segments must be flanked on both sides by recombination signals that are in the proper orientation with respect to one another. In the examples below the two parental nucleic acid molecules (e.g., plasmids) are called the Insert Donor and the Vector Donor. The Insert Donor contains a segment that will become joined to a new vector contributed by the Vector Donor. The recombination intermediate(s) that contain(s) both starting molecules is called the Cointegrate(s). The second recombination event produces two daughter molecules, called the Product (the desired new clone) and the Byproduct.

### *Buffers*

Various known buffers can be used in the reactions of the present invention. For restriction enzymes, it is advisable to use the buffers recommended by the manufacturer. Alternative buffers can be readily found in the literature or can be devised by those of ordinary skill in the art.

*Examples 1-3.* One exemplary buffer for lambda integrase is comprised of 50 mM Tris-HCl, at pH 7.5-7.8, 70 mM KCl, 5 mM spermidine, 0.5 mM EDTA, and 0.25 mg/ml bovine serum albumin, and optionally, 10% glycerol.

One preferred buffer for P1 Cre recombinase is comprised of 50 mM Tris-HCl at pH 7.5, 33 mM NaCl, 5 mM spermidine, and 0.5 mg/ml bovine serum albumin.

The buffer for other site-specific recombinases which are similar to lambda Int and P1 Cre are either known in the art or can be determined

empirically by the skilled artisans, particularly in light of the above-described buffers.

**Example 1: Recombinational Cloning Using Cre and Cre & Int**

Two pairs of plasmids were constructed to do the *in vitro* recombinational cloning method in two different ways. One pair, pEZC705 and pEZC726 (Figure 2A), was constructed with *loxP* and *att* sites, to be used with Cre and  $\lambda$  integrase. The other pair, pEZC602 and pEZC629 (Figure 3A), contained the *loxP* (wild type) site for Cre, and a second mutant *lox* site, *loxP 511*, which differs from *loxP* in one base (out of 34 total). The minimum requirement for recombinational cloning of the present invention is two recombination sites in each plasmid, in general *X* and *Y*, and *X'* and *Y'*. Recombinational cloning takes place if either or both types of site can recombine to form a Cointegrate (e.g. *X* and *X'*), and if either or both (but necessarily a site different from the type forming the Cointegrate) can recombine to excise the Product and Byproduct plasmids from the Cointegrate (e.g. *Y* and *Y'*). It is important that the recombination sites on the same plasmid do not recombine. It was found that the present recombinational cloning could be done with Cre alone.

**Cre-Only**

Two plasmids were constructed to demonstrate this conception (see Figure 3A). pEZC629 was the Vector Donor plasmid. It contained a constitutive drug marker (chloramphenicol resistance), an origin of replication, *loxP* and *loxP 511* sites, a conditional drug marker (kanamycin resistance whose expression is controlled by the operator/promoter of the tetracycline resistance operon of transposon *Tn10*), and a constitutively expressed gene for the tet repressor protein, *tetR*. *E. coli* cells containing pEZC629 were resistant to chloramphenicol at 30  $\mu$ g/ml, but sensitive to kanamycin at 100  $\mu$ g/ml. pEZC602 was the Insert Donor plasmid, which contained a different drug marker

(ampicillin resistance), an origin, and *loxP* and *loxP* 511 sites flanking a multiple cloning site.

This experiment was comprised of two parts as follows:

**Part I:** About 75 ng each of pEZC602 and pEZC629 were mixed in a total volume of 30  $\mu$ l of Cre buffer (50 mM Tris-HCl pH 7.5, 33 mM NaCl, 5 mM spermidine-HCl, 500  $\mu$ g/ml bovine serum albumin). Two 10  $\mu$ l aliquots were transferred to new tubes. One tube received 0.5  $\mu$ l of Cre protein (approx. 4 units per  $\mu$ l; partially purified according to Abremski and Hoess, *J. Biol. Chem.* 259:1509 (1984)). Both tubes were incubated at 37°C for 30 minutes, then 70°C for 10 minutes. Aliquots of each reaction were diluted and transformed into DH5 $\alpha$ . Following expression, aliquots were plated on 30  $\mu$ g/ml chloramphenicol; 100  $\mu$ g/ml ampicillin plus 200  $\mu$ g/ml methicillin; or 100  $\mu$ g/ml kanamycin. **Results:** See Table 1. The reaction without Cre gave  $1.11 \times 10^6$  ampicillin resistant colonies (from the Insert Donor plasmid pEZC602);  $7.8 \times 10^5$  chloramphenicol resistant colonies (from the Vector Donor plasmid pEZC629); and 140 kanamycin resistant colonies (background). The reaction with added Cre gave  $7.5 \times 10^5$  ampicillin resistant colonies (from the Insert Donor plasmid pEZC602);  $6.1 \times 10^5$  chloramphenicol resistant colonies (from the Vector Donor plasmid pEZC629); and 760 kanamycin resistant colonies (mixture of background colonies and colonies from the recombinational cloning Product plasmid). **Analysis:** Because the number of colonies on the kanamycin plates was much higher in the presence of Cre, many or most of them were predicted to contain the desired Product plasmid.

Table 1

Enzyme	Ampicillin	Chloramphenicol	Kanamycin	Efficiency
None	$1.1 \times 10^6$	$7.8 \times 10^5$	140	$140/7.8 \times 10^5 = 0.02\%$
Cre	$7.5 \times 10^5$	$6.1 \times 10^5$	760	$760/6.1 \times 10^5 = 0.12\%$

**Part II:** Twenty four colonies from the "+ Cre" kanamycin plates were picked and inoculated into medium containing 100  $\mu$ g/ml kanamycin. Minipreps were done, and the miniprep DNAs, uncut or cut with *Sma*I or *Hind*III, were

electrophoresed. **Results:** 19 of the 24 minipreps showed supercoiled plasmid of the size predicted for the Product plasmid. All 19 showed the predicted *Sma*I and *Hind*III restriction fragments. **Analysis:** The Cre only scheme was demonstrated. Specifically, it was determined to have yielded about 70% (19 of 24) Product clones. The efficiency was about 0.1% (760 kanamycin resistant clones resulted from  $6.1 \times 10^5$  chloramphenicol resistant colonies).

### *Cre Plus Integrase*

The plasmids used to demonstrate this method are exactly analogous to those used above, except that pEZC726, the Vector Donor plasmid, contained an *attP* site in place of *loxP* 511, and pEZC705, the Insert Donor plasmid, contained an *attB* site in place of *loxP* 511 (Figure 2A).

This experiment was comprised of three parts as follows:

**Part I:** About 500 ng of pEZC705 (the Insert Donor plasmid) was cut with *Sca*I, which linearized the plasmid within the ampicillin resistance gene. (This was done because the  $\lambda$  integrase reaction has been historically done with the *attB* plasmid in a linear state (H. Nash, personal communication). However, it was found later that the integrase reaction proceeds well with both plasmids supercoiled.) Then, the linear plasmid was ethanol precipitated and dissolved in 20  $\mu$ l of  $\lambda$  integrase buffer (50 mM Tris-HCl, about pH 7.8, 70 mM KCl, 5 mM spermidine-HCl, 0.5 mM EDTA, 250  $\mu$ g/ml bovine serum albumin). Also, about 500 ng of the Vector Donor plasmid pEZC726 was ethanol precipitated and dissolved in 20  $\mu$ l  $\lambda$  integrase buffer. Just before use,  $\lambda$  integrase (2  $\mu$ l, 393  $\mu$ g/ml) was thawed and diluted by adding 18  $\mu$ l cold  $\lambda$  integrase buffer. One  $\mu$ l IHF (integration host factor, 2.4 mg/ml, an accessory protein) was diluted into 150  $\mu$ l cold  $\lambda$  integrase buffer. Aliquots (2  $\mu$ l) of each DNA were mixed with  $\lambda$  integrase buffer, with or without 1  $\mu$ l each  $\lambda$  integrase and IHF, in a total of 10  $\mu$ l. The mixture was incubated at 25°C for 45 minutes, then at 70°C for 10 minutes. Half of each reaction was applied to an agarose gel. **Results:** In the presence of integrase and IHF, about 5% of the total DNA was converted to a linear Cointegrate form. **Analysis:** Activity of integrase and IHF was confirmed.

**Part II:** Three microliters of each reaction (*i.e.*, with or without integrase and IHF) were diluted into 27  $\mu$ l of Cre buffer (above), then each reaction was split into two 10  $\mu$ l aliquots (four altogether). To two of these reactions, 0.5  $\mu$ l of Cre protein (above) were added, and all reactions were incubated at 37°C for 30 minutes, then at 70°C for 10 minutes. TE buffer (90  $\mu$ l; TE: 10 mM Tris-HCl, pH 7.5, 1 mM EDTA) was added to each reaction, and 1  $\mu$ l each was transformed into *E. coli* DH5 $\alpha$ . The transformation mixtures were plated on 100  $\mu$ g/ml ampicillin plus 200  $\mu$ g/ml methicillin; 30  $\mu$ g/ml chloramphenicol; or 100  $\mu$ g/ml kanamycin. **Results:** See Table 2.

Table 2				
Enzyme	Ampicillin	Chloramphenicol	Kanamycin	Efficiency
None	990	20000	4	$4 / 2 \times 10^4 = 0.02\%$
Cre only	280	3640	0	0
Integrase* only	1040	27000	9	$9 / 2.7 \times 10^4 = 0.03\%$
Integrase* + Cre	110	1110	76	$76 / 1.1 \times 10^3 = 6.9\%$

\* Integrase reactions also contained IHF.

**Analysis:** The Cre protein impaired transformation. When adjusted for this effect, the number of kanamycin resistant colonies, compared to the control reactions, increased more than 100 fold when both Cre and Integrase were used. This suggests a specificity of greater than 99%.

**Part III:** 38 colonies were picked from the Integrase plus Cre plates, miniprep DNAs were made and cut with *Hind*III to give diagnostic mapping information. **Result:** All 38 had precisely the expected fragment sizes. **Analysis:** The Cre plus  $\lambda$  integrase method was observed to have much higher specificity than Cre-alone. **Conclusion:** The Cre plus  $\lambda$  integrase method was demonstrated. Efficiency and specificity were much higher than for Cre only.

**Example 2: Using *in vitro* Recombinational Cloning to Subclone the Chloramphenicol Acetyl Transferase Gene into a Vector for Expression in Eukaryotic Cells (Figure 4A)**

An Insert Donor plasmid, pEZC843, was constructed, comprising the chloramphenicol acetyl transferase gene of *E. coli*, cloned between *loxP* and *attB* sites such that the *loxP* site was positioned at the 5'-end of the gene (Figure 4B). A Vector Donor plasmid, pEZC1003, was constructed, which contained the cytomegalovirus eukaryotic promoter apposed to a *loxP* site (Figure 4C). One microliter aliquots of each supercoiled plasmid (about 50 ng crude miniprep DNA) were combined in a ten microliter reaction containing equal parts of lambda integrase buffer (50 mM Tris-HCl, pH 7.8, 70 mM KCl, 5 mM spermidine, 0.5 mM EDTA, 0.25 mg/ml bovine serum albumin) and Cre recombinase buffer (50 mM Tris-HCl, pH 7.5, 33 mM NaCl, 5 mM spermidine, 0.5 mg/ml bovine serum albumin), two units of Cre recombinase, 16 ng integration host factor, and 32 ng lambda integrase. After incubation at 30°C for 30 minutes and 75°C for 10 minutes, one microliter was transformed into competent *E. coli* strain DH5 $\alpha$  (Life Technologies, Inc.). Aliquots of transformations were spread on agar plates containing 200  $\mu$ g/ml kanamycin and incubated at 37°C overnight. An otherwise identical control reaction contained the Vector Donor plasmid only. The plate receiving 10% of the control reaction transformation gave one colony; the plate receiving 10% of the recombinational cloning reaction gave 144 colonies. These numbers suggested that greater than 99% of the recombinational cloning colonies contained the desired product plasmid. Miniprep DNA made from six recombinational cloning colonies gave the predicted size plasmid (5026 base pairs), CMVProd. Restriction digestion with *NcoI* gave the fragments predicted for the chloramphenicol acetyl transferase cloned downstream of the CMV promoter for all six plasmids.

**Example 3: Subcloned DNA Segments Flanked by attB Sites Without Stop Codons**

**Part I: Background**

The above examples are suitable for transcriptional fusions, in which transcription crosses recombination sites. However, both attR and loxP sites contain multiple stop codons on both strands, so translational fusions can be difficult, where the coding sequence must cross the recombination sites, (only one reading frame is available on each strand of loxP sites) or impossible (in attR or attL).

A principal reason for subcloning is to fuse protein domains. For example, fusion of the glutathione S-transferase (GST) domain to a protein of interest allows the fusion protein to be purified by affinity chromatography on glutathione agarose (Pharmacia, Inc., 1995 catalog). If the protein of interest is fused to runs of consecutive histidines (for example His6), the fusion protein can be purified by affinity chromatography on chelating resins containing metal ions (Qiagen, Inc.). It is often desirable to compare amino terminal and carboxy terminal fusions for activity, solubility, stability, and the like.

The attB sites of the bacteriophage  $\lambda$  integration system were examined as an alternative to loxP sites, because they are small (25 bp) and have some sequence flexibility (Nash, H.A. *et al.*, *Proc. Natl. Acad. Sci. USA* 84:4049-4053 (1987). It was not previously suggested that multiple mutations to remove all stop codes would result in useful recombination sites for recombinational subcloning.

Using standard nomenclature for site specific recombination in lambda bacteriophage (Weisber, in *Lambda III*, Hendrix, *et al.*, eds., Cold Spring Harbor

- 38 -

Laboratory, Cold Spring Harbor, NY (1989)), the nucleotide regions that participate in the recombination reaction in an *E. coli* host cell are represented as follows:

```

5      attP  --P1--H1--P2--X--H2--C-O-C--H'--P'1--P'2--P'3--
              +
      attB              --B-O-B'--
              Int, IHF II Xis, Int, IHF

      attR  --P1--H1--P2--X--H2--C-O-B'--
              +
10     attL              --B-O-C--H'--P'1--P'2--P'3--
  
```

where: O represents the 15 bp core DNA sequence found in both the phage and *E. coli* genomes; B and B' represent approximately 5 bases adjacent to the core in the *E. coli* genome; and P1, H1, P2, X, H2, C, C', H, P'1, P'2, and P'3 represent known DNA sequences encoding protein binding domains in the bacteriophage  $\lambda$  genome.

The reaction is reversible in the presence of the protein Xis (excisionase); recombination between attL and attR precisely excise the  $\lambda$  genome from its integrated state, regenerating the circular  $\lambda$  genome containing attP and the linear *E. coli* genome containing attB.

## Part II: Construction and Testing of Plasmids Containing Mutant att Sites

Mutant attL and attR sites were constructed. Importantly, Landy *et al.* (*Ann. Rev. Biochem.* 58:913 (1989)) observed that deletion of the P1 and H1 domains of attP facilitated the excision reaction and eliminated the integration reaction, thereby making the excision reaction irreversible. Therefore, as mutations were introduced in attR, the P1 and H1 domains were also deleted. attR sites in the present example lack the P1 and H1 regions and have the NdeI site removed (base 27630 changed from C to G), and contain sequences



corresponding to bacteriophage  $\lambda$  coordinates 27619-27738 (GenBank release 92.0, bg:LAMCG, "Complete Sequence of Bacteriophage Lambda").

The sequence of attB produced by recombination of wild type attL and attR sites is:

```

      B           O           B'
5  attBwt:      5'  AGCCT  GCTTTTTTATACTAA  CTGTA  3'  (SEQ. ID
                                     NO:31)
      3'  TCGGA  CGAAAAAATATGATT  GAACT  5'

```

The stop codons are italicized and underlined. Note that sequences of attL, attR, and attP can be derived from the attB sequence and the boundaries of bacteriophage  $\lambda$  contained within attL and attR (coordinates 27619 to 27818).

When mutant attR1 and attL1 sites were recombined the sequence attB1 was produced (mutations in bold, large font):

```

      B           O           B'
attB1:      5'  AGCCT  GCTTTTTTGTACAAA  CTTGT  3'  (SEQ. ID NO:6)
      3'  TCGGA  CGAAAAAACATGTTT  GACAA  5'

```

Note that the four stop codons are gone.

When an additional mutation was introduced in the attR1 and attL1 sequences (**bold**), attR2 and attL2 sites resulted. Recombination of attR2 and attL2 produced the attB2 site:

```

      B           O           B'
attB2:      5'  AGCCT  GCTTTCTGTGACAAA  CTTGT  3'  (SEQ. ID NO:7)
      3'  TCGGA  CGAAAGAACATGTTT  GACAA  5'

```

The recombination activities of the above attL and attR sites were assayed as follows. The attB site of plasmid pEZC705 (Figure 2B) was replaced with

attLwt, attL1, or attL2. The attP site of plasmid pEYC726 (Figure 2C) was replaced with attRwt (lacking regions P1 and H1), attR1, or attR2. Thus, the resulting plasmids could recombine via their loxP sites, mediated by Cre, and via their attR and attL sites, mediated by Int, Xis, and IHF. Pairs of plasmids were mixed and reacted with Cre, Int, Xis, and IHF, transformed into *E. coli* competent cells, and plated on agar containing kanamycin. The results are presented in Table 3:

Table 3

Vector donor att site	Gene donor att site	# of kanamycin resistant colonies*
attRwt (pEYC1301)	None	1 (background)
"	attLwt (pEYC1313)	147
"	attL1 (pEYC1317)	47
"	attL2 (pEYC1321)	0
attR1 (pEYC1305)	None	1 (background)
"	attLwt (pEYC1313)	4
"	attL1 (pEYC1317)	128
"	attL2 (pEYC1321)	0
attR2 (pEYC1309)	None	9 (background)
"	attLwt (pEYC1313)	0
"	attL1 (pEYC1317)	0
"	attL2 (pEYC1321)	209

(\*1% of each transformation was spread on a kanamycin plate.)

The above data show that whereas the wild type att and att1 sites recombine to a small extent, the att1 and att2 sites do not recombine detectably with each other.

**Part III.** Recombination was demonstrated when the core region of both attB sites flanking the DNA segment of interest did not contain stop codons. The physical state of the participating plasmids was discovered to influence recombination efficiency.

The appropriate att sites were moved into pEYC705 and pEYC726 to make the plasmids pEYC1405 (Figure 5G) (attR1 and attR2) and pEYC1502 (Figure 5H) (attL1 and attL2). The desired DNA segment in this experiment was a copy of the chloramphenicol resistance gene cloned between the two attL sites

of pEZC1502. Pairs of plasmids were recombined *in vitro* using Int, Xis, and IHF (no Cre because no loxP sites were present). The yield of desired kanamycin resistant colonies was determined when both parental plasmids were circular, or when one plasmid was circular and the other linear as presented in Table 4:

Table 4

Vector donor <sup>1</sup>	Gene donor <sup>1</sup>	Kanamycin resistant colonies <sup>2</sup>
Circular pEZC1405	None	30
Circular pEZC1405	Circular pEZC1502	2680
Linear pEZC1405	None	90
Linear pEZC1405	Circular pEZC1502	172000
Circular pEZC1405	Linear pEZC1502	73000

<sup>1</sup> DNAs were purified with Qiagen columns, concentrations determined by A260, and linearized with Xba I (pEZC1405) or AlwN I (pEZC1502). Each reaction contained 100 ng of the indicated DNA. All reactions (10 µl total) contained 3 µl of enzyme mix (Xis, Int, and IHF). After incubation (45 minutes at 25°, 10 minutes at 65°), one µl was used to transform *E. coli* DH5α cells.

<sup>2</sup> Number of colonies expected if the entire transformation reaction (1 ml) had been plated. Either 100 µl or 1 µl of the transformations were actually plated.

**Analysis:** Recombinational cloning using mutant attR and attL sites was confirmed. The desired DNA segment is subcloned between attB sites that do not contain any stop codons in either strand. The enhanced yield of Product DNA (when one parent was linear) was unexpected because of earlier observations that the excision reaction was more efficient when both participating molecules were supercoiled and proteins were limiting (Nunes-Duby *et al.*, *Cell* 50:779-788 (1987).

#### Example 4: Demonstration of Recombinational Cloning Without Inverted Repeats

##### Part I: Rationale

The above Example 3 showed that plasmids containing inverted repeats of the appropriate recombination sites (for example, attL1 and attL2 in plasmid pEZC1502) (Figure 5H) could recombine to give the desired DNA segment

flanked by attB sites without stop codons, also in inverted orientation. A concern was the *in vivo* and *in vitro* influence of the inverted repeats. For example, transcription of a desired DNA segment flanked by attB sites in inverted orientation could yield a single stranded RNA molecule that might form a hairpin structure, thereby inhibiting translation.

Inverted orientation of similar recombination sites can be avoided by placing the sites in direct repeat arrangement att sites. If parental plasmids each have a wild type attL and wild type attR site, in direct repeat the Int, Xis, and IHF proteins will simply remove the DNA segment flanked by those sites in an intramolecular reaction. However, the mutant sites described in the above Example 3 suggested that it might be possible to inhibit the intramolecular reaction while allowing the intermolecular recombination to proceed as desired.

#### ***Part II: Structure of Plasmids Without Inverted Repeats for Recombinational Cloning***

The attR2 sequence in plasmid pEZC1405 (Figure 5G) was replaced with attL2, in the opposite orientation, to make pEZC1603 (Figure 6A). The attL2 sequence of pEZC1502 (Figure 5H) was replaced with attR2, in the opposite orientation, to make pEZC1706 (Figure 6B). Each of these plasmids contained mutations in the core region that make intramolecular reactions between att1 and att2 cores very inefficient (see Example 3, above).

Plasmids pEZC1405, pEZC1502, pEZC1603 and pEZC1706 were purified on Qiagen columns (Qiagen, Inc.). Aliquots of plasmids pEZC1405 and pEZC1603 were linearized with Xba I. Aliquots of plasmids pEZC1502 and pEZC1706 were linearized with AlwN I. One hundred ng of plasmids were mixed in buffer (equal volumes of 50 mM Tris HCl pH 7.5, 25 mM Tris HCl pH 8.0, 70 mM KCl, 5 mM spermidine, 0.5 mM EDTA, 250 µg/ml BSA, 10% glycerol) containing Int (43.5 ng), Xis (4.3 ng) and IHF (8.1 ng) in a final volume of 10 µl. Reactions were incubated for 45 minutes at 25°C, 10 minutes at 65°C, and 1 µl was transformed into *E. coli* DH5α. After expression, aliquots were spread on agar plates containing 200 µg/ml kanamycin and incubated at 37°C.

Results, expressed as the number of colonies per 1  $\mu$ l of recombination reaction are presented in Table 5:

Table 5

Vector Donor	Gene Donor	Colonies	Predicted % product
Circular 1405	---	100	---
Circular 1405	Circular 1502	3740	3640/3740 = 97%
Linear 1405	---	90	---
Linear 1405	Circular 1502	172,000	171,910/172,000 = 99.9%
Circular 1405	Linear 1502	73,000	72,900/73,000 = 99.9%
Circular 1603	---	80	---
Circular 1603	Circular 1706	410	330/410 = 80%
Linear 1603	---	270	---
Linear 1603	Circular 1706	7000	6730/7000 = 96%
Circular 1603	Linear 1706	10,800	10,530/10,800 = 97%

**Analysis.** In all configurations, i.e., circular or linear, the pEYC1405 x pEYC1502 pair (with att sites in inverted repeat configuration) was more efficient than pEYC1603 x pEYC1706 pair (with att sites mutated to avoid hairpin formation). The pEYC1603 x pEYC1706 pair gave higher backgrounds and lower efficiencies than the pEYC1405 x pEYC1502 pair. While less efficient, 80% or more of the colonies from the pEYC1603 x pEYC1706 reactions were expected to contain the desired plasmid product. Making one partner linear stimulated the reactions in all cases.

### Part III: Confirmation of Product Plasmids' Structure

Six colonies each from the linear pEYC1405 (Figure 5G) x circular pEYC1502 (Figure 5H), circular pEYC1405 x linear pEYC1502, linear pEYC1603 (Figure 6A) x circular pEYC1706 (Figure 6B), and circular pEYC1603 x linear pEYC1706 reactions were picked into rich medium and

miniprep DNAs were prepared. Diagnostic cuts with Ssp I gave the predicted restriction fragments for all 24 colonies.

*Analysis.* Recombination reactions between plasmids with mutant attL and attR sites on the same molecules gave the desired plasmid products with a high degree of specificity.

*Example 5: Recombinational Cloning with a Toxic Gene*

*Part I: Background*

Restriction enzyme Dpn I recognizes the sequence GATC and cuts that sequence only if the A is methylated by the dam methylase. Most commonly used *E. coli* strains are dam<sup>+</sup>. Expression of Dpn I in dam<sup>+</sup> strains of *E. coli* is lethal because the chromosome of the cell is chopped into many pieces. However, in dam<sup>-</sup> cells expression of Dpn I is innocuous because the chromosome is immune to Dpn I cutting.

In the general recombinational cloning scheme, in which the vector donor contains two segments C and D separated by recombination sites, selection for the desired product depends upon selection for the presence of segment D, and the absence of segment C. In the original Example segment D contained a drug resistance gene (Km) that was negatively controlled by a repressor gene found on segment C. When C was present, cells containing D were not resistant to kanamycin because the resistance gene was turned off.

The Dpn I gene is an example of a toxic gene that can replace the repressor gene of the above embodiment. If segment C expresses the Dpn I gene product, transforming plasmid CD into a dam<sup>+</sup> host kills the cell. If segment D is transferred to a new plasmid, for example by recombinational cloning, then selecting for the drug marker will be successful because the toxic gene is no longer present.

*Part II: Construction of a Vector Donor Using Dpn I as a Toxic Gene*

The gene encoding Dpn I endonuclease was amplified by PCR using primers 5'CCA CCA CAA ACG CGT CCA TGG AAT TAC ACT TTA ATT TAG3' (SEQ. ID NO: 17) and 5'CCA CCA CAA GTC GAC GCA TGC CGA CAG CCT TCC AAA TGT3' (SEQ. ID NO:18) and a plasmid containing the Dpn I gene (derived from plasmids obtained from Sanford A. Lacks, Brookhaven National Laboratory, Upton, New York; also available from American Type Culture Collection as ATCC 67494) as the template.

Additional mutations were introduced into the B and B' regions of attL and attR, respectively, by amplifying existing attL and attR domains with primers containing the desired base changes. Recombination of the mutant attL3 (made with oligo Xis115) and attR3 (made with oligo Xis112) yielded attB3 with the following sequence (differences from attB1 in bold):

B                      O                      B'

15      ACCCA GCTTTCTGTACAAA GTGGT (SEQ. ID NO:8)  
 TGGGT CGAAGAACATGTTT CACCA

The attL3 sequence was cloned in place of attL2 of an existing Gene Donor plasmid to give the plasmid pEZC2901 (Figure 7A). The attR3 sequence was cloned in place of attR2 in an existing Vector Donor plasmid to give plasmid pEZC2913 (Figure 7B) Dpn I gene was cloned into plasmid pEZC2913 to replace the tet repressor gene. The resulting Vector Donor plasmid was named pEZC3101 (Figure 7C). When pEZC3101 was transformed into the dam<sup>-</sup> strain SCS110 (Stratagene), hundreds of colonies resulted. When the same plasmid was transformed into the dam<sup>+</sup> strain DH5 $\alpha$ , only one colony was produced, even though the DH5 $\alpha$  cells were about 20 fold more competent than the SCS110 cells. When a related plasmid that did not contain the Dpn I gene was transformed into the same two cell lines, 28 colonies were produced from the SCS110 cells, while 448 colonies resulted from the DH5 $\alpha$  cells. This is evidence

that the Dpn I gene is being expressed on plasmid pEJC3101 (Figure 7C), and that it is killing the *dam*<sup>+</sup> DH5 $\alpha$  cells but not the *dam*<sup>-</sup> SCS110 cells.

### *Part III: Demonstration of Recombinational Cloning Using Dpn I Selection*

A pair of plasmids was used to demonstrate recombinational cloning with selection for product dependent upon the toxic gene Dpn I. Plasmid pEJC3101 (Figure 7C) was linearized with Mlu I and reacted with circular plasmid pEJC2901 (Figure 7A). A second pair of plasmids using selection based on control of drug resistance by a repressor gene was used as a control: plasmid pEJC1802 (Figure 7D) was linearized with Xba I and reacted with circular plasmid pEJC1502 (Figure 5H). Eight microliter reactions containing the same buffer and proteins Xis, Int, and IHF as in previous examples were incubated for 45 minutes at 25°C, then 10 minutes at 75°C, and 1  $\mu$ l aliquots were transformed into DH5 $\alpha$  (i.e., *dam*<sup>+</sup>) competent cells, as presented in Table 6.

*Table 6*

Reaction #	Vector donor	Basis of selection	Gene donor	Colonies
1	pEJC3101/Mlu	Dpn I toxicity	—	3
2	pEJC3101/Mlu	Dpn I toxicity	Circular pEJC2901	4000
3	pEJC1802/Xba	Tet repressor	—	0
4	pEJC1802/Xba	Tet repressor	Circular pEJC1502	12100

Miniprep DNAs were prepared from four colonies from reaction #2, and cut with restriction enzyme Ssp I. All gave the predicted fragments.

**Analysis:** Subcloning using selection with a toxic gene was demonstrated. Plasmids of the predicted structure were produced.



***Example 6: Cloning of Genes with Uracil DNA Glycosylase and Subcloning of the Genes with Recombinational Cloning to Make Fusion Proteins***

***Part I: Converting an Existing Expression Vector to a Vector Donor for Recombinational Cloning***

5           A cassette useful for converting existing vectors into functional Vector Donors was made as follows. Plasmid pEZC3101 (Figure 7C) was digested with Apa I and Kpn I, treated with T4 DNA polymerase and dNTPs to render the ends blunt, further digested with Sma I, Hpa I, and AlwN I to render the undesirable DNA fragments small, and the 2.6 kb cassette containing the attR1 - Cm<sup>R</sup> - Dpn I  
10 - attR-3 domains was gel purified. The concentration of the purified cassette was estimated to be about 75 ng DNA/ $\mu$ l.

          Plasmid pGEX-2TK (Figure 8A) (Pharmacia) allows fusions between the protein glutathione S transferase and any second coding sequence that can be inserted in its multiple cloning site. pGEX-2TK DNA was digested with Sma I  
15 and treated with alkaline phosphatase. About 75 ng of the above purified DNA cassette was ligated with about 100 ng of the pGEX-2TK vector for 2.5 hours in a 5  $\mu$ l ligation, then 1  $\mu$ l was transformed into competent BRL 3056 cells (a dam<sup>-</sup> derivative of DH10B; dam<sup>-</sup> strains commercially available include DM1 from Life Technologies, Inc., and SCS 110 from Stratagene). Aliquots of the transformation mixture were plated on LB agar containing 100  $\mu$ g/ml ampicillin  
20 (resistance gene present on pGEX-2TK) and 30  $\mu$ g/ml chloramphenicol (resistance gene present on the DNA cassette). Colonies were picked and miniprep DNAs were made. The orientation of the cassette in pGEX-2TK was determined by diagnostic cuts with EcoR I. A plasmid with the desired  
25 orientation was named pEZC3501 (Figure 8B).

***Part II: Cloning Reporter Genes Into an Recombinational Cloning Gene Donor Plasmid in Three Reading Frames***

Uracil DNA glycosylase (UDG) cloning is a method for cloning PCR  
amplification products into cloning vectors (U.S. patent No. 5,334,515, entirely  
5 incorporated herein by reference). Briefly, PCR amplification of the desired  
DNA segment is performed with primers that contain uracil bases in place of  
thymidine bases in their 5' ends. When such PCR products are incubated with the  
enzyme UDG, the uracil bases are specifically removed. The loss of these bases  
weakens base pairing in the ends of the PCR product DNA, and when incubated  
10 at a suitable temperature (e.g., 37°C), the ends of such products are largely single  
stranded. If such incubations are done in the presence of linear cloning vectors  
containing protruding 3' tails that are complementary to the 3' ends of the PCR  
products, base pairing efficiently anneals the PCR products to the cloning vector.  
When the annealed product is introduced into *E. coli* cells by transformation, *in*  
15 *vivo* processes efficiently convert it into a recombinant plasmid.

UDG cloning vectors that enable cloning of any PCR product in all three  
reading frames were prepared from pEZC3201 (Figure 8K) as follows. Eight  
oligonucleotides were obtained from Life Technologies, Inc. (all written 5' - 3':  
20 **rf1 top** (GGCC GAT TAC GAT ATC CCA ACG ACC GAA AAC CTG TAT  
TTT CAG GGT) (SEQ. ID NO:19), **rf1 bottom** (CAG GTT TTC GGT CGT  
TGG GAT ATC GTA ATC) (SEQ. ID NO:20), **rf2 top** (GGCCA GAT TAC  
GAT ATC CCA ACG ACC GAA AAC CTG TAT TTT CAG GGT) (SEQ. ID  
NO:21), **rf2 bottom** (CAG GTT TTC GGT CGT TGG GAT ATC GTA  
ATC T) (SEQ. ID NO:22), **rf3 top** (GGCCAA GAT TAC GAT ATC CCA ACG  
25 ACC GAA AAC CTG TAT TTT CAG GGT) (SEQ. ID NO:23), **rf3 bottom**  
(CAG GTT TTC GGT CGT TGG GAT ATC GTA ATC TT) (SEQ. ID NO:24),  
**carboxy top** (ACC GTT TAC GTG GAC) (SEQ. ID NO:25) and **carboxy**  
**bottom** (TCGA GTC CAC GTA AAC GGT TCC CAC TTA TTA) (SEQ. ID  
NO:26). The rf1, 2, and 3 top strands and the carboxy bottom strand were  
30 phosphorylated on their 5' ends with T4 polynucleotide kinase, and then the  
complementary strands of each pair were hybridized. Plasmid pEZC3201

(Figure 8K) was cut with Not I and Sal I, and aliquots of cut plasmid were mixed with the carboxy-oligo duplex (Sal I end) and either the rf1, rf2, or rf3 duplexes (Not I ends) (10 µg cut plasmid (about 5 pmol) mixed with 250 pmol carboxy oligo duplex, split into three 20 µl volumes, added 5 µl (250 pmol) of rf1, rf2, or rf3 duplex and 2 µl = 2 units T4 DNA ligase to each reaction). After 90 minutes of ligation at room temperature, each reaction was applied to a preparative agarose gel and the 2.1 kb vector bands were eluted and dissolved in 50 µl of TE.

### Part III: PCR of CAT and phoA Genes

Primers were obtained from Life Technologies, Inc., to amplify the chloramphenicol acetyl transferase (CAT) gene from plasmid pACYC184, and phoA, the alkaline phosphatase gene from *E. coli*. The primers had 12-base 5' extensions containing uracil bases, so that treatment of PCR products with uracil DNA glycosylase (UDG) would weaken base pairing at each end of the DNAs and allow the 3' strands to anneal with the protruding 3' ends of the rf1, 2, and 3 vectors described above. The sequences of the primers (all written 5' - 3') were: CAT left, UAU UUU CAG GGU ATG GAG AAA AAA ATC ACT GGA TAT ACC (SEQ. ID NO:27); CAT right, UCC CAC UUA UUA CGC CCC GCC CTG CCA CTC ATC (SEQ. ID NO:28); phoA left, UAU UUU CAG GGU ATG CCT GTT CTG GAA AAC CGG (SEQ. ID NO:29); and phoA right, UCC CAC UUA UUA TTT CAG CCC CAG GGC GGC TTT C (SEQ. ID NO:30). The primers were then used for PCR reactions using known method steps (see, e.g., U.S. patent No. 5,334,515, entirely incorporated herein by reference), and the polymerase chain reaction amplification products obtained with these primers comprised the CAT or phoA genes with the initiating ATGs but without any transcriptional signals. In addition, the uracil-containing sequences on the amino termini encoded the cleavage site for TEV protease (Life Technologies, Inc.), and those on the carboxy terminal encoded consecutive TAA nonsense codons.

Unpurified PCR products (about 30 ng) were mixed with the gel purified, linear rf1, rf2, or rf3 cloning vectors (about 50 ng) in a 10 µl reaction containing 1X REact 4 buffer (LTI) and 1 unit UDG (LTI). After 30 minutes at 37°C, 1 µl

aliquots of each reaction were transformed into competent *E. coli* DH5 $\alpha$  cells (LTI) and plated on agar containing 50  $\mu$ g/ml kanamycin. Colonies were picked and analysis of miniprep DNA showed that the CAT gene had been cloned in reading frame 1 (pEZC3601)(Figure 8C), reading frame 2 (pEZC3609)(Figure 8D) and reading frame 3 (pEZC3617)(Figure 8E), and that the phoA gene had been cloned in reading frame 1 (pEZC3606)(Figure 8F), reading frame 2 (pEZC3613)(Figure 8G) and reading frame 3 (pEZC3621)(Figure 8H).

**Part IV: Subcloning of CAT or phoA from UDG Cloning Vectors into a GST Fusion Vector**

Plasmids encoding fusions between GST and either CAT or phoA in all three reading frames were constructed by recombinational cloning as follows. Miniprep DNA of GST vector donor pEZC3501(Figure 8B) (derived from Pharmacia plasmid pGEX-2TK as described above) was linearized with Cla I. About 5 ng of vector donor were mixed with about 10 ng each of the appropriate circular gene donor vectors containing CAT or phoA in 8  $\mu$ l reactions containing buffer and recombination proteins Int, Xis, and IHF (above). After incubation, 1  $\mu$ l of each reaction was transformed into *E. coli* strain DH5 $\alpha$  and plated on ampicillin, as presented in Table 7.

**Table 7**

DNA	Colonies (10% of each transformation)
Linear vector donor (pEZC3501/Cla)	0
Vector donor + CAT rf1	110
Vector donor + CAT rf2	71
Vector donor + CAT rf3	148
Vector donor + phoA rf1	121
Vector donor + phoA rf2	128
Vector donor + phoA rf3	31

*Part V: Expression of Fusion Proteins*

Two colonies from each transformation were picked into 2 ml of rich medium (CircleGrow, Bio101 Inc.) in 17 × 100 mm plastic tubes (Falcon 2059, Becton Dickinson) containing 100 µg/ml ampicillin and shaken vigorously for about 4 hours at 37°C, at which time the cultures were visibly turbid. One ml of each culture was transferred to a new tube containing 10 µl of 10% (w/v) IPTG to induce expression of GST. After 2 hours additional incubation, all cultures had about the same turbidity; the A600 of one culture was 1.5. Cells from 0.35 ml each culture were harvested and treated with sample buffer (containing SDS and β-mercaptoethanol) and aliquots equivalent to about 0.15 A600 units of cells were applied to a Novex 4-20% gradient polyacrylamide gel. Following electrophoresis the gel was stained with Coomassie blue.

**Results:** Enhanced expression of single protein bands was seen for all 12 cultures. The observed sizes of these proteins correlated well with the sizes predicted for GST being fused (through attB recombination sites without stop codons) to CAT or phoA in three reading frames: CAT rf1 = 269 amino acids; CAT rf2 = 303 amino acids; CAT rf3 = 478 amino acids; phoA rf1 = 282 amino acids; phoA rf2 = 280 amino acids; and phoA rf3 = 705 amino acids.

**Analysis:** Both CAT and phoA genes were subcloned into a GST fusion vector in all three reading frames, and expression of the six fusion proteins was demonstrated.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims. All patents and publications cited herein are entirely incorporated herein by reference.

*What Is Claimed Is:*

1. A Vector Donor DNA molecule comprising a first DNA segment and a second DNA segment, said first or second DNA segment containing at least one Selectable marker, wherein the first and second segments are separated either by, (i) in a circular Vector Donor, a first and a second recombination site, or (ii) in a linear Vector Donor, at least a first recombination site, wherein each pair of flanking recombination sites are engineered and do not recombine with each other.

2. A Vector Donor DNA molecule according to claim 1, wherein the Selectable marker is at least one DNA segment selected from the group consisting of:

- (i) a DNA segment that encodes a product that provides resistance against otherwise toxic compounds;
- (ii) a DNA segment that encodes a product that is otherwise lacking in the recipient cell;
- (iii) a DNA segment that encodes a product that suppresses the activity of a gene product;
- (iv) a DNA segment that encodes a product that can be readily identified;
- (v) a DNA segment that encodes a product that is detrimental to cell survival and/or function;
- (vi) a DNA segment that inhibits the activity of any of the DNA segments of (i)-(v) above ;
- (vii) a DNA segment that binds a product that modifies a substrate;
- (viii) a DNA segment that provides for isolation of a desired molecule; and
- (ix) a DNA segment that encodes a specific nucleotide sequence which can be otherwise non-functional; and

- (x) a DNA segment that, when absent, directly or indirectly confers sensitivity to particular compounds.

3. A Vector Donor DNA according to claim 2, wherein said Selectable marker is at least one selected from the group consisting of an antibiotic resistance gene, a tRNA gene, an auxotrophic marker, a toxic gene, a phenotypic marker, an antisense oligonucleotide; a restriction endonuclease; a restriction endonuclease cleavage site, an enzyme cleavage site, a protein binding site; and a sequence complementary PCR primer.

4. A Vector Donor DNA molecule according to claim 1, wherein said Selectable marker comprises at least one inactive fragment of a Selectable marker, wherein the inactive fragment is capable of reconstituting a functional Selectable marker when recombined across said first or second recombination site with a further DNA segment comprising another inactive fragment of the Selectable marker.

5. An Insert Donor DNA molecule, comprising a desired DNA segment flanked by a first recombination site and a second recombination site, wherein the first and second recombination sites are engineered and do not recombine with each other.

6. An Insert Donor DNA molecule according to claim 5, wherein said desired DNA segment codes for at least one selected from the group consisting of a cloning site, a restriction site, a promoter, an operon, an origin of replication, a functional DNA, an antisense RNA, a PCR fragment, a protein or a protein fragment.

7. A kit comprising a container being compartmentalized to receive in close confinement therein at one compartment, wherein a first compartment contains a Vector Donor DNA molecule comprising a first DNA segment and a second DNA segment, said first or second DNA segment containing at least one

Selectable marker, wherein the first and second segments are flanked either by, (i) in a circular Vector Donor, a first and a second recombination site, or (ii) in a linear Vector Donor, a first recombination site, wherein each pair of flanking recombination sites are engineered and do not recombine with each other.

5           8.     A kit according to claim 7, further comprising a second compartment containing an Insert Donor DNA molecule comprising a desired DNA segment flanked by a first recombination site and a second recombination site, wherein the first and second recombination sites are engineered and do not recombine with each other.

10           9.     A kit according to claim 7, further comprising an additional compartment containing at least one recombination protein capable of recombining a DNA segment comprising at least one of said recombination sites.

15           10.    A nucleic acid molecule, comprising at least one DNA segment having at least two recombination sites flanking a Selectable marker or a desired DNA segment, wherein at least one of said recombination sites comprises a core region having at least one engineered mutation that enhances recombination *in vitro* in the formation of a Cointegrate DNA or a Product DNA.

20           11.    A nucleic acid molecule according to claim 10, wherein said mutation confers at least one enhancement of said recombination, said enhancement selected from the group consisting of substantially (i) favoring excisive recombination; (ii) favoring integrative recombination; (iii) relieving the requirement for host factors; (iv) increasing the efficiency of said Cointegrate DNA or Product DNA formation; (v) increasing the specificity of said Cointegrate DNA or Product DNA formation; and contributes desirable attributes to the  
25           Product DNA.



12. A nucleic acid molecule according to claim 10, wherein said recombination site is derived from at least one recombination site selected from the group consisting of attB, attP, attL and attR.

5 13. A nucleic acid molecule according to claim 12, wherein said att site is selected from the groups consisting of att1, att2 and att3.

14. A nucleic acid according to claim 10, wherein said core region comprises a DNA sequence selected from the group consisting of:

- 10 (a) RKYCWGCTTTTYKTRTACNAASTSGB (m-att) (SEQ ID NO:1);  
(b) AGCCWGCTTTTYKTRTACNAACTSGB (m-attB) (SEQ ID NO:2);  
(c) GTTCAGCTTTCKTRTACNAACTSGB (m-attR) (SEQ ID NO:3);  
(d) AGCCWGCTTTCKTRTACNAACTSGB (m-attL) (SEQ ID NO:4);  
15 (e) GTTCAGCTTTTYKTRTACNAACTSGB(m-attP1) (SEQ ID NO:5);

and a corresponding or complementary DNA or RNA sequence, wherein R=A or G; K=G or T/U; Y=C or T/U; W=A or T/U; N=A or C or G or T/U; S=Cor G; and B=C or G or T/U.

20 15. A nucleic acid according to claim 14, wherein said core region comprises a DNA sequence selected from the group consisting of:

- 25 (a) AGCCTGCTTTTTTGACAAACTTGT (attB1) (SEQ ID NO:6);  
(b) AGCCTGCTTCTTGACAAACTTGT (attB2) (SEQ ID NO:7);  
(c) ACCCAGCTTCTTGACAAACTTGT (attB3) (SEQ ID NO:8);  
(d) GTTCAGCTTTTTTGACAAACTTGT (attR1) (SEQ ID NO:9);  
(e) GTTCAGCTTCTTGACAAACTTGT (attR2) (SEQ ID NO:10);  
(f) GTTCAGCTTCTTGACAAAGTTGG (attR3) (SEQ ID NO:11);

- (g) AGCCTGCTTTTTTGTACAAAGTTGG (attL1) (SEQ ID NO:12);
- (h) AGCCTGCTTTCTTGTACAAAGTTGG (attL2) (SEQ ID NO:13);
- 5 (i) ACCCAGCTTTCTTGTACAAAGTTGG (attL3) (SEQ ID NO:14);
- (j) GTTCAGCTTTTTTGTACAAAGTTGG(attP1)(SEQ ID NO:15);
- (k) GTTCAGCTTTCTTGTACAAAGTTGG (attP2,P3) (SEQ ID NO:16);
- 10 and a corresponding or complementary DNA or RNA sequence.

16. A method for making a nucleic acid molecule, comprising providing a nucleic acid molecule having at least one engineered recombination site comprising at least one DNA sequence having at least 90% homology to at least one of SEQ ID NOS:1-16.
- 15 17. A nucleic acid molecule provided by a method according to claim 16.
18. A composition, comprising a nucleic acid molecule according to claim 10.
19. A kit, comprising a container being compartmentalized to receive in close confinement therein at least one compartment, wherein a first compartment contains a composition according to claim 18.
- 20 20. A kit according to claim 19, further comprising a second compartment having at least one recombination protein that recognizes said recombination site.

21. A kit comprising a container being compartmentalized to receive in close confinement therein at least one recombination protein in isolated form, useful for a method according to claim 22.

22. A method of making a Cointegrate DNA molecule, comprising combining *in vitro*:

- (i) an Insert Donor DNA molecule, comprising a desired DNA segment flanked by a first recombination site and a second recombination site, wherein the first and second recombination sites do not recombine with each other;
- (ii) a Vector Donor DNA molecule containing a third recombination site and a fourth recombination site, wherein the third and fourth recombination sites do not recombine with each other; and
- (iii) at least one site specific recombination protein capable of recombining said first and third recombinational sites said second and fourth recombinational sites;

thereby allowing recombination to occur, so as to produce a Cointegrate DNA molecule comprising said first and third or said second and fourth recombination sites.

23. A method according to claim 22, wherein a Product DNA molecule is produced from said Cointegrate DNA by recombining at least one of (i) said first and third, or (ii) said second and fourth, recombination sites, said Product DNA comprising said desired DNA segment.

24. A method according to claim 23, wherein said method also produces a Byproduct DNA molecule.

25. A method according to claim 23, further comprising selecting for the Product DNA molecule.

26. A method as claimed in claim 22, wherein the Vector Donor DNA molecule comprises a vector segment flanked by said third and the fourth recombination sites.
- 5 27. A method as claimed in claim 22, wherein the Vector Donor DNA molecule further comprises (a) a toxic gene and (b) a Selectable marker, wherein the toxic gene and the Selectable marker are on different DNA segments, the DNA segments being separated either by (i) in a circular DNA molecule, two recombination sites, or (ii) in a linear DNA molecule, one recombination site.
- 10 28. A method as claimed in claim 22, wherein the Vector Donor DNA molecule further comprises (a) a repression cassette and (b) a Selectable marker, repressed by the repressor of the repression cassette, and wherein the Selectable marker and the repression cassette are on different DNA segments, the DNA segments being separated either by, (i) in a circular DNA molecule, two recombination sites, or (ii) in a linear DNA molecule, one recombination site.
- 15 29. A method as claimed in claim 22, wherein at least one of the Insert Donor DNA molecule and the Vector Donor DNA molecule is a circular DNA molecule.
- 20 30. A method as claimed in claim 22, wherein at least one of the Insert Donor DNA molecule and the Vector Donor DNA molecule is a linear DNA molecule.
31. A method as claimed in claim 22, wherein the selecting step is carried out *in vitro* or *in vivo*.
- 25 32. A method as claimed in claim 22, wherein said recombination protein comprises at least a first recombination protein and a second recombination protein, said second recombination protein being different from said first recombination protein.

33. A method as claimed in claim 22, wherein said recombination protein is Int.

34. A method as claimed in claim 22, wherein the at least one recombination protein is selected from (i) Int and IHF and (ii) Int, Xis, and IHF.






Figure 1

2/44



- FIGURE 2A -


3/44



- FIGURE 2B -



4/44




- FIGURE 2C -






7/44




- FIGURE 2F -




- FIGURE 3A -

5/44




- FIGURE 3B -

10/44



- FIGURE 3C -


11/44



- FIGURE 3D -




12/44



- FIGURE 3E -




14/44




- FIGURE 4A -

15/44




- FIGURE 4B -

16/44




- FIGURE 4C -

17/44



- FIGURE 4D -


18/44



- FIGURE 4E -









- FIGURE 5A -

21/44




- FIGURE 5B -

22/44




- FIGURE 5C -

23/44




- FIGURE 5D -

24/44




- FIGURE 5E -

25/44




- FIGURE 5F -

26/44




27/44



- FIGURE 5H -




28/44




- FIGURE 6A -

29/44




- FIGURE 6B -

30/44




- FIGURE 7A -

31/44




- FIGURE 7B -

32/44




- FIGURE 7C -

33/44




- FIGURE 7D -

34/44



- FIGURE 8A -


35/44



- FIGURE 8B -




36/44




- FIGURE 8C -

37/44




- FIGURE 8D -

38/44




- FIGURE 8E -

39/44




- FIGURE 8F -

40/44




- FIGURE 8G -

4/1/44




- FIGURE 8H -

42/44



- FIGURE 8I -


43/44



- FIGURE 8J -



44/44



- FIGURE 8K -

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/10082

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : C07H 21/04; C12N 15/00, 15/63 US CL : 435/172.3, 320.1; 536/23.1 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/172.3, 320.1; 536/23.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P ----- Y, P	US 5,434,066 A (BEBEE et al.) 18 July 1995, columns 2-10, especially: column 2, line 53 to column 3, line 13; column 4, lines 49-52; and column 9, lines 41-53.	1-11,18-32 ----- 1-11,18-32
X -- Y	EP 0 300 422 A2 (E.I. DU PONT DE NEMOURS AND COMPANY) 25 January 1989, especially pages 2-9.	1-11,18-32 ----- 1-11,18-32
X -- Y	BRUNELLI et al. Lambda/Plasmid Vector Construction by In Vivo cre/lox-Mediated Recombination. BioTechniques. June 1994, Vol. 16, No. 6, pages 1060 and 1062-1064, especially pages 1060 and 1062.	1-11,18-32 ----- 1-11,18-32
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to underlain the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family		
Date of the actual completion of the international search 16 SEPTEMBER 1996		Date of mailing of the international search report 10 OCT 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer THANDA WAI <i>[Signature]</i> Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/10082

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-14(a) and 16-34

Remark on Protest

☐  
☐

- The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/10082

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, BIOSIS, CAPLUS, WPIDS

search terms: cre, recombinase, integrase, resolvase, recombination, chimeric DNA, site-specific, site-directed

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

Group I, claims 1-14 and 16-34, species election of claim 14 (a), (b), (c), (d), or (e).

Group II, claims 1-13 and 15-34, species election of claim 15 (a), (b), (c), (d), (e), (f), (g), (h), (i), or (k).

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the sequences disclosed lack a common core and require separate searches. Accordingly, they are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single general inventive concept.